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Calpains are regulatory calcium ion activated cysteine proteases present in nearly all 
eukaryotes (1). Dysregulation of Ca2+ homeostasis, which results in aberrant calpain 
activation is implicated in contributing to age-related pathologies, such as Alzheimer’s 
disease and sarcopenia (2,3). However, it has been difficult to identify substrates targeted 
by calpain activation, because cleavage specificity is not determined by primary sequence 
alone (4). 
 
Calpains are categorised into typical and atypical based on their domain architecture. 
Current understanding of human calpain activity is based primarily on studies of ‘typical’ 
calpains, which contain EF hand domains; less is understood about the six ‘atypical’ 
calpains that lack this domain. The genome of the model organism Caenorhabditis 
elegans encodes only atypical calpain proteins. Earlier studies have shown that these 
proteins are differentially expressed in a variety of tissues (5). Overexpression of CLP-1 in 
body wall muscle was shown to cause a low penetrance paralysis accompanied by muscle 
degeneration in adults (5). The severity of paralysis increased when CLP-1 was 
overexpressed in egl-19(gf) mutants that produce elevated levels of intracellular calcium. 
The substrates targeted by CLP-1 are unknown. 
 
To identify potential CLP-1 substrates, a proteomic screen was performed. A CLP-
1::mRFP fusion protein was expressed in muscle and protein complexes co-purifying with 
CLP-1 after immunoprecipitation were identified by mass spectrometry. A bioinformatics 
tool WormGRAB was created to collect information on proteins identified by mass 





were identified from the proteomic screen as well as other potential substrates that had not 
been previously associated with maintenance of muscle. 
 
Further analysis of the intracellular localisation of CLP-1 in body wall muscle was also 
pursued to understand how it might be targeted to substructures of the sarcomere. The 
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1 Introduction  
1.1 Overview of Calpains  
 
 
Calpains are a family of calcium activated intracellular non-lysosomal cysteine proteases. 
Calpains were first purified from rat tissue by Guroff in 1964, and the name calpain was 
proposed by Murachi et al. in 1981 in recognition of their similarity to the calcium binding 
proteins calmodulin and the cysteine protease papain from papaya (6,7). Whole genome 
sequencing projects have shown that genes encoding predicted calpain products are 
present in a wide and extensive range of eukaryotes and eubacteria (8). They are 
commonly classified into typical and atypical groups, depending on the presence or 
absence respectively; of calcium binding EF-hand domains (Figure 1) (1). Calpains are 
now defined by presence of a Cysteine Protease Core domain CysPC (also referred to as 
domain II), which contains the catalytic triad (Figure 1). These multi-domain proteins are 
further classified based on their domain composition and expression pattern.  
 
Unlike strictly degradative proteases, such as lysosomal proteases, which digest 
substrates into non-functional polypeptides and amino acids, calpains cleave substrates in 
a limited manner to produce a functional product with modulated activity. For this reason, 
calpains are often referred to as modulatory or regulatory proteases (9). Calpains are 
implicated as participating in numerous cellular processes; however their precise role is 
unclear in these processes due to a lack of identified physiological substrates (10).  
 
Calpains are potential therapeutic targets as they are associated with a number of 
degenerative diseases including Alzheimer’s disease (3). Limb girdle muscular dystrophy 
type 2a (LGMD2a), which is also referred to as calpainopathy, is caused by a mutation in 
the human muscle specific calpain gene CAPN3 (11). There are 15 calpain genes present 






1.2 Calpain structure and classification 
 
Calpains are commonly classified by their domain organisation into ‘typical’ and ‘atypical‘ 
calpains. Typical calpains, all of which have a cysteine protease core domain, are further 
defined by their structural similarity to vertebrate CAPN1 and CAPN2, each of which have 
a penta EF-hand (PEF) domain and C2-Like domain (Figure 2) (10). Atypical calpains lack 
the PEF domain and might also lack C2-L domains. Recent phylogenetic analyses of 
calpains have revealed that the PEF hand domain of typical calpains was an evolutionarily 
late addition (8). This suggests that the PEF hand domain might act in conjunction with the 
vertebrate calpain small subunit (CAPNS) to enable binding of the endogenous inhibitor 
calpastatin as an additional regulatory mechanism (8,12). Despite the greater abundance 
of genes encoding atypical calpains across eukaryotes, the majority of research has 




Calpains are present in eukaryotes and bacteria, but are absent from archaea (8). 
Eukaryotic calpains are likely to have originated by horizontal gene transfer from bacteria 
(13). Whereas bacteria have been found to express at most one calpain gene, eukaryotes 
may express several calpain genes with different domain architectures. Calpains are 
present in the vast majority of eukaryotes leading to earlier hypothesis that calpains are 
essential genes in eukaryotes, but they have been found to be absent from several 
unicellular eukaryotes (8). 
 
As shown in Figure 1, phylogenetic analysis of eukaryotes has revealed the existence of 
four ancestral domain architectures (CysPC, CysPc-C2L, TML-CysPc-C2l, MIT-CysPc-





domains have evolved relatively recently in eukaryotes, and are absent in bacteria, 
represent a minority subset of the calpain family (13). Typical calpains have evolved 
several regulatory mechanisms; EF-hand domains, small subunit interaction, calpastatin 
interaction (1). Although activity of atypical calpains are likely to be primarily regulated by 
calcium ion levels, other regulatory mechanisms may exist amongst the variety of domains 









Figure 1. Eukaryotic calpain phylogeny. 
The clades representing four proposed ancestral domain architectures are color-coded 
(i.e. CysPc in dark brown, CysPc-C2L in blue, MIT-CysPc-C2L in light green and TML-
CysPc-C2L in dark green). 








1.2.2 Structure and characterisation 
 
The characterisation of the calpain family has primarily focused on the typical calpains μ-
calpain and m-calpain (known today as CAPN1 and CAPN2). These proteins are named  
according to the micro and milli molar concentrations of Ca2+, respectively, at which they 
become proteolytically activated in vitro (14). CAPN1 and CAPN2 are expressed 
ubiquitously in mammals (15). Despite the difference in their Ca2+ requirements, CAPN1 
and CAPN2 (Figure 2) share over 60% amino acid identity and are both inhibited by the 
only identified endogenous calpain inhibitor calpastatin (1,16). Although CAPN1 and 
CAPN2 were originally suspected to have similar substrate specificity, more recent studies 
have revealed differences in substrate preferences for each protease (17).  
 
The typical calpains CAPN1 and CAPN2 each consist of a large catalytic subunit that 
associates with a common small regulatory subunit CAPNS. CAPNS is encoded by a 
separate gene. As shown in Figure 2, the large subunit ~80 kDa is organised into four 
domains (I-IV) and the small subunit ~28 kDa two domains (V-VI) (10). Domain boundaries 
were refined when the crystal structure of rat and human m-calpain was solved (18,19). 
Domain I consists of an α-helix that acts as an anchor between the protease core domain 
and the regulatory subunit domain VI. Domain I undergoes autolysis, which in turn lowers 
the concentration of Ca2+ required for proteolytic activity (Figure 3) (20). Autolysis is one of 








Figure 2. Human typical calpain CAPN1 and C. elegans atypical calpain CLP-1 
proteins. 
Domain architecture of the human typical CAPN1 and CAPNS (μ-calpain), and the C. 
elegans non-classical calpain CLP-1. CysPC domain is the proteolytic domain. C2-L refers 
to a calmodulin like domain. PEF domain contains 5 EF-hand motifs. GR refers to a 
glycine rich region in CLP-1. 
 
 
Figure 3. Anchor helix domain 1 undergoes autolysis allowing calpain activation. 
 Autolysis of domain 1 is hypothesised to promote PC1 and PC2 to undergo a 
conformational change activating the catalytic triad (20). Figure adapted from Campbell et 
al. 2012 (20). 
  
CAPN1, H. sapiens 
 
CAPNS, H. sapiens 
 






Calpains are defined based on their amino acid sequence similarity to the protease core 
domain CysPC (domain II). CysPC contains an active site that houses the catalytic triad of 
cysteine, histidine and asparagine. The catalytic triad facilitates substrate proteolysis by 
covalent catalysis via nucleophilic substitution (22). The cysteine is activated by a nearby 
histidine, which is polarised after alignment with the asparagine.  The crystal structure of 
Ca2+ free CAPN2 revealed that domain II consists of two subdomains PC1 and PC2 
(Figure 3). PC1 contains the cysteine residue, which is 10.5 angstroms away from the 
histidine and asparagine of the catalytic triad. Binding of Ca2+ to the N-terminal anchor 
helix and CysPC causes a conformational change in PC1 and PC2, which was observed in 
the crystal structure of Ca2+ bound CAPN1 (see Figure 4). This conformational change 
brings the amino acids of the catalytic triad in close proximity to one another, causing the 








Figure 4. Schematic of the 3D structure of inactive human CAPN2 and Ca2+ activated 
rat CAPN2. 
Unbound and calcium ion bound crystal structures of human and rat CAPN2 represented 
by cartoon 3D structures overlaid on ‘surface’ structures are shown. Binding of Ca2+ cause 
a conformational change resulting in activation of the catalytic triad. Image adapted from 
Sorimachi et al. 2011 (1).
Domain III shares a similar 3-dimensional structure to a C2 domain, but it shares little 
sequence similarity and is therefore referred to as a C2-like domain (C2-L). C2 domains 
are Ca2+ regulated lipid binding domains found in many enzymes. It is postulated that 
calpain translocation to phospholipid membranes is facilitated by the C2-L domain (25). 
However, there is also evidence that the N-terminal glycine rich hydrophobic domain V 
(GR) of the regulatory subunit might be of greater significance for membrane binding 
(25,26). 
 
Domain IV is composed of a PEF domain. EF hands are helix-loop-helix motifs that 
typically bind calcium ions. However, the fifth EF hand in Domain IV binds with the fifth EF 
hand of another PEF domain in the regulatory subunit (domain VI), resulting in 
heterodimerisation of the large and small subunits (27,28). Atypical calpains do not have a 
PEF domain and therefore do not associate with a regulatory subunit (29). 
 
In addition to the protease core domain atypical calpains also include a variety of repeated 
domains and other domains not found in typical calpains. A survey of calpain diversity in a 
representative sample of eukaryotic organisms revealed 24 different domains, including 
zinc fingers, microtubule interacting domains and glycine rich regions found in combination 
with the CysPc domain (8). The presence or absence of these domains are used to 
classify atypical calpains into different subfamilies (Figure 5): The PalB subfamily, which is 
found in humans, nematodes and other species, has two C2-L domains at its C-terminus 
(1). The SOH subfamily is characterised by presence of Zinc finger motifs at their N-
terminus and a small optic lobe (SOL) homologue domain at their C-terminus. The DEK-1 
subfamily has one C2-L domain and often an N-terminal trans-membrane domain, which 






Figure 5. Classical or typical calpains and non-classical or atypical calpains and 
subfamilies.  
Subfamilies are differentiated by the presence or absence of domains outside of the 
catalytic core PC1 and PC2 domains. Image adapted from Sorimachi et al. 2011 (30). 
 
1.3 Substrate specificity of calpain. 
 
Calpains have been proposed to act as ‘modulator’ proteases because they digest their 
substrates in a limited manner, affecting their longevity, localisation or activity. Calpain 
proteolysis can result in aberrant signal transduction or facilitate subsequent degradation 







The substrate specificity of calpain is primarily determined by the 3-dimensional 
conformation of the substrate. Studies using peptide libraries to identify potential calpain 
substrates have identified consensus residues favoured by calpain proteases. However, 
the sequences identified using peptide libraries often differ from known substrate cleavage 
sequences (4). It is thus hypothesised that the substrate specificity of calpains is only 
weakly determined by primary sequence (4,17). For this reason, it has been difficult to 
identify calpain substrates and to predict sites of proteolysis. The deep cleft of the CysPC 
domain suggests that the substrate needs to be in an exposed loop conformation (4,24).  
 
Over 100 substrates for calpains have been identified in vitro (10). These substrates can 
be grouped into four distinct types: cytoskeletal proteins, membrane-associated proteins, 
transcription factors, and kinases and phosphatases. Substrates identified in vitro are not 
necessarily in vivo physiological substrates. For example, fibronectin is degraded in vitro, 
but is unlikely to be an in vivo physiological substrate as it is an extracellular protein. 
Calpains are exclusively intracellular, except in pathological conditions (10). 
  
1.4 Physiological roles of calpain 
 
The conservation of calpain proteases across eukaryotic and some eubacterial phyla 
suggests that calpain function is important for eukaryotic life. The full-range of 
physiological functions of typical and atypical calpains is not well understood; however, It 
has been shown that calpains are involved in cytoskeletal remodelling, apoptosis, sex 
determination, signal transduction, gene expression regulation and the cell cycle (10,31). 
Most of this knowledge has been gained by using calpain inhibitors or genetic methods to 
reduce or enhance calpain activity. Calpain has been implicated to be a key mediator of 





of tumour suppressor p53 was reduced in cells that had been treated with MDL 28170, an 
active site targeting reversible membrane permeable peptidic calpain inhibitor. A similar 
reduction in p53 activity was obtained in cells derived from CAPNS (small regulatory 
subunit) knockout mice (32).  
 
CAPN1 and CAPN2 were shown to have essential functions in CAPNS -/- knock out mice 
(33). Knockout of both CAPN1 and CAPN2 caused embryonic lethality after 11 days of 
gestation. Singly mutant CAPN1 -/- mice had no embryonic defects, but adults had an 
impaired platelet-platelet aggregation phenotype (34). These results suggest that CAPN1’s 
function can mostly be replaced by CAPN2, and that CAPN1 has a specific signalling role 
in platelet aggregation. CAPN2 -/- mice failed to develop past the preimplantation stage 
(35), indicating that CAPN2 is physiologically more important than CAPN1.  Histological 
samples of muscle tissue from CAPN3 -/- mice exhibited similar defects to those found in 
LGMD2a caused by mutations in the human CAPN3 gene (36). 
 
CAPN1 and CAPN2 are inhibited by the only known endogenous calpain inhibitor 
calpastatin (Figure 6) (1,16). Calpastatin contains four inhibitory subunits that each inhibit 
calpain by binding the PEF domains IV and VI and CysPC domain. Calpastatin does not 
bind atypical calpains, which lack PEF-hand domains (37). NMR studies show that the 
calpastatin peptide normally assumes a random coil conformation (38). Calpastatin exists 










Figure 6. Calpastatin structure, Inhibition of typical calpains by calpastatin.  
A: Calpastatin contains an L domain of unknown function and 4 repetitive inhibitory 
domains with A, B and C regions that can competitively bind and inhibit typical calpains 
(37). B: Calpastatin binds the penta EF-hand domains of typical calpains. Figure adapted 
from Chakraborti et. al 2012 (39). 
 
Calpain inhibitors are classified into reversible and irreversible peptidic and reversible non-
peptidic inhibitors. Many of these inhibitors are not specific to calpains and are capable of 
binding other cysteine and even serine proteases (10,40). Peptidic inhibitors include 
reversible inhibitors leupeptin and calpeptin, and irreversible inhibitor E-64, however these 
inhibitors are not selective for calpains. The non-peptidic small molecule inhibitor 
PD150606 inhibits calpain by an unknown mechanism by binding in a region outside of the 
active site (41). With the promise of therapeutic use, the identification of calpain inhibitors 
is an active area of drug discovery, with the aim of identifying calpain specific inhibition 
(42). 
 
Cell motility is one of the most extensively studied processes involving calpains (31). 
Inhibition of calpain proteolysis has been shown to reduce focal adhesion complex 
A   B   C         A   B   C        A   B   C        A   B   C 
 
 












turnover, thus inhibiting cell motility and cell spreading. Focal adhesions are large protein 
complexes connecting the cytoskeleton with the extra cellular matrix (ECM) (31). CAPN1 
and CAPN2 cleave components of adhesion complexes found at the rear of polarised 
cells, including talin and focal adhesion kinase (FAK). This results in detachment of the 








Figure 7. CAPN2 cleaves focal adhesion complex components facilitating cell 
migration. 
Influx of calcium from calcium ion channels near to focal adhesion complexes activates 
CAPN2 which cleaves focal adhesion components including talin and FAK, allowing 
retraction of the rear of the cell from the extracellular matrix (44,45). Figure adapted from 
Saraiva et al. 2013 (45). 
 
 
Calpains have an important role in cell-cycle regulation, and the crosstalk between 
autophagy and apoptosis (46). Autophagic cell death can occur as a fail-safe mechanism 
when apoptosis fails due to insufficient activation of caspase proteases (47). In human 
cells, overexpression of the autophagy factor ATG-5 increased autophagy and sensitised 
cells to undergo receptor and stress mediated cellular death (46). ATG-5 was shown to be 
cleaved by calpain to produce a functional product that translocates to mitochondria and 
inhibits the anti-apoptotic molecule Bcl-xL, triggering cytochrome c release and apoptotic 
cell death. 
 
Calpains have been shown to inhibit autophagy; key autophagy proteins ATG5 and BEC-1 
are cleaved by calpains (46,48). However, paradoxically calpain is also required for 







1.5 Calpain pathologies 
 
1.5.1 Pathologies associated with typical calpains 
 
The calpain-cathepsin hypothesis proposes that calpains promote necrotic cell death by 
permeabilising the lysosomal membrane resulting in cytosolic acidosis and release of 
cathepsin proteases (Figure 8). This hypothesis was proposed by Yamashima after it was 
found calpains congregate to lysosomal membranes after ischemic events (50). Support 
for this hypothesis was obtained in C. elegans after it was found that CLP-1 and TRA-3 
were required for necrotic cell death in synergy with lysosomal (cathepsin) aspartyl 
proteases asp-3 and asp-4 (51).  
 
Figure 8. The calpain-cathepsin hypothesis. 
Increase of cytosolic Ca2+ levels resulting from an influx from ion channels or intracellular 
stores after a necrosis triggering event, causes calpain activation. In turn calpains migrate 
to the lysosome where they permeabilise the lysosome and release cathepsin proteases. 
Cathepsins general degradation of cellular proteins results in necrotic cell death (50). 







Diseases associated with calpains are classified into two types: genetic diseases 
associated with reduced or loss of calpain activity and diseases associated with over 
activity of calpains caused by elevated intracellular calcium levels or mutations that result 
in constitutive activity usually leading to degenerative pathologies.  
 
Muscular dystrophies are denoted by the atrophy of muscle cells and tissues, and resulting 
progressive muscle weakness and degeneration (52). Nearly all muscular dystrophies 
involve the loss of Ca2+ homeostasis (29). The majority of muscular dystrophy diseases 
are caused by mutations in genes that encode structural proteins. However, LGMD2a is a 
form of muscular dystrophy that primarily affects the shoulder and pelvic musculature, and 
is caused by mutations in the gene encoding the skeletal muscle specific CAPN3 (11). 
Mutations that affect the ability of CAPN3 to degrade a protein substrate are hypothesised 
to be responsible for this disease (53). Increased apoptosis and changes in the localisation 
profile of nuclear factor κB (NF-κB) have been observed in LGMD2a patients (54). NF-κB 
is a transcription factor that drives expression of several survival genes (55). CAPN3 
overexpression has also been identified as an aggravating factor in a mouse model of 
muscular dystrophy, showing the importance of CAPN3 regulation in normal physiology 
(54). 
 
Human typical calpains CAPN8 and CAPN9 form a heterodimer in vivo. Both proteins are 
expressed predominantly in surface mucus cells of the stomach and intestine (56). Pit cells 
are essential in maintaining the stomach lining by secreting bicarbonate and neutral 
mucous. CAPN8 and CAPN9 knockout mice showed a significant increase in susceptibility 
to gastric mucosal injury. Expression of the CAPN9 gene is down-regulated in gastric 






The majority of degenerative pathologies associated with calpains are those in which 
calpains are overactive due to disrupted Ca2+ homeostasis, resulting in elevated 
intracellular Ca2+ levels. Aging is one of the processes linked to increased Ca2+ disruption; 
however, many conditions can cause Ca2+ disruption including heat stress. Dysregulation 
of calpain activity is associated with several diseases including Alzheimer’s disease, 
cataract formation, Duchenne and Becker’s muscular dystrophy, myocardial infarction, 
multiple sclerosis and neuronal ischemia (10). Calpains have been identified as acting 
upstream of two key biochemical features of Alzheimer’s disease; amyloid beta protein 
formation (senile plaques) and tau protein hyperphosphorylation resulting neurofibrillary 
tangles (57). Typical calpains have also been shown to cleave tau proteins and cleave 
hyperphosphorylated tau proteins with diminished efficiency (58). CAPN2 is hypothesised 
to act upstream of both of these pathological events, regulating the activity of neuronal 
developmental protein CDK5 kinase and GSKB kinase (59), and is therefore viewed as a 
potential therapeutic candidate for Alzheimer’s disease (57,60).  
 
CAPN2 cleaves alpha and beta crystalline following increase of calcium ion concentration 
of 20 fold caused by injury or aging (61), disrupting crystalline lattices that increase 
refractive index, resulting in cataract formation (62). 
 
1.5.2 Pathologies associated with atypical calpains 
 
Mutations in the atypical calpain CAPN10 gene are associated with an increased risk of 
having Type 2 diabetes mellitus (63). The disease is characterised by high blood pressure 
and high glucose levels in the blood caused by insulin resistance or inadequate insulin 
secretion. CAPN10 inhibition results in the decrease of insulin-stimulated uptake and also 





The majority of diseases associated with calpains are attributed to aberration of typical 
calpains. Atypical calpains are less well characterised and may also be contributing to 
disease phenotypes. In this study I focus on pathologies associated with atypical calpains 
using C. elegans which expresses only atypical calpains. 
 
1.6 C. elegans as a model organism 
 
C. elegans is a free-living nematode worm adopted as a model organism by Sydney 
Brenner in an extensive forward genetic mapping study (64). Brenner chose C. elegans as 
a model to study the eukaryotic nervous system due to its relatively simple nervous system 
(302 neurons), transparency, and other advantageous characteristics (65) including: small 
size of adults (1 mm), inexpensive growth on E. coli (64), a rapid life cycle of 3.5 days at 
20 °C, and hermaphrodite and male sexes that are convenient for genetic analysis. 
 
Since Brenner initiated studies with C. elegans, several developments have increased its 
appeal as a model organism for biomedical research. The lineage and anatomy of the C. 
elegans hermaphrodite have been fully described, including the developmental fate of all 
959 somatic cells found in hermaphrodite adults and 1031 somatic cells in adult males 
(65,66). C. elegans was also the first multicellular eukaryotic organism to have its whole 
genome sequenced in 1998, enabling bioinformatics methods for gene identification and 
reverse genetic studies of all C. elegans genes (67). More recently RNA interference and 
whole genome feeding libraries methods have been developed (68). As protein mass 
spectrometry technology has advanced, biochemical techniques for protein analysis have 
also been developed facilitating proteomic investigation (69). Due to the ease of 
generating transgenic lines, forward genetics, RNAi and high throughput chemical screens 
as well as the conservation in cell physiology, with 38% of C. elegans proteins having 
human homologues (70), C. elegans has been used as a disease model for 





as muscular diseases and metabolic diseases (71). Several strains expressing human 
amyloid-beta protein in different tissues have been generated (71,72).  
 
Whole genome sequence analysis of C. elegans has identified 10 genes encoding calpain 
proteins (5). The C. elegans atypical calpains CLP-1 and CLP-4 are expressed in body 
wall muscle cells (5). In this project, I have focused on identifying potential substrates of 
the C. elegans calpain-1 (CLP-1) protein. In addition, I initiated studies to understand the 
basis of the intracellular localisation of CLP-1 in body wall muscle. CLP-1 has a glycine 
rich N-terminus, an α-helix domain 1, a CysPC domain and a C2-like domain (Figure 2) 







1.7 C. elegans muscle  
 
There are several muscle groups found in C. elegans with distinct functions; body 
wall muscle used for locomotion, pharyngeal muscle for feeding, intestinal muscles 
for digestion, vulval muscle cells for egg-laying (74). 
  
The fundamental contractile unit in C. elegans muscle is the sarcomere (Figure 9). 
Sarcomeres form repeated units in body wall muscle giving rise to the observed 
striated pattern, or form single units in non-striated muscles, such as the pharyngeal 
pumping muscle cells. Sarcomeres consist of actin thin filaments that are anchored 
to the cell membrane via attachments to dense bodies (homologous to vertebrate z-
lines) (Figure 9). Actin thin filaments are interspersed with myosin thick filaments, 
which are anchored to the cell membrane by M-lines. M-lines form rows that are 
interdigitated with dense bodies. Attachment plaques are found at muscle-muscle 
junctions (74,75). There are a variety of different proteins found in the integrin 
attachment complexes (M-lines, dense bodies and attachment plaques) (Figure 9). 
C. elegans striated muscle has been used as a model for studying human muscle as 







Figure 9. C. elegans Sarcomere. 
Adapted from Moerman and Williams 2006 (76). The sarcomere comprises of dense 
body and m-line attachment complexes, which contain a variety of proteins some of 
which are important for normal muscle physiology (76). RNAi knockdown of 
sarcomeric proteins unc-97 and unc-112 induced mass protein degradation, 







1.8 The atypical calpains of C. elegans  
 
Name Expression* Notes 
clp-1 Muscle, neuron, intestine, hypodermis Required for neuronal necrotic cell death 
(51). Overexpression causes paralysis 
phenotype (5). 
clp-2 Intestine - 
clp-3 - - 
clp-4 Muscle, neuron,  hypodermis, excretory 
cell 
- 
clp-5/tra-3 Neuron, intestine,  hypodermis, excretory 
cell 
Required for correct sex determination 
(78). Required for neuronal necrotic cell 
death (51). 
clp-6 - - 
clp-7 Neuron, intestine,  hypodermis, excretory 
cell, seam cell 
- 
clp-8 - - 
clp-9 Pharynx, hypodermis, nervous system, 
tail, reproductive system 
- 
clp-10 - clp-10 (ok2713) mutant has 50% 
reduction brood size (5). 
clpr-1 - Missing catalytic cysteine (5). 
clpr-2 - Missing catalytic cysteine (5). 
clpr-3 - Missing catalytic cysteine (5). 
clpr-4 - Missing catalytic cysteine (5). 
 
Table 1. The calpains of C. elegans.  
10 genes encoding atypical calpains are present in the C. elegans genome along 
with 4 clp-related genes that lack a complete catalytic triad and so do not have 
proteolytic activity (5). *Expression refers to evidence antibody staining of tagged 






Whole genome sequence analysis of C. elegans identified 10 genes encoding 
calpain proteins and 4 genes encoding calpain-like proteins, which have an 
incomplete catalytic triad (Table 1), all of which are lacking PEF domains. 
 
TRA-3 (Calpain-5, CLP-5) is a C. elegans atypical calpain that plays a role in 
nematode sex-determination (78). TRA-3 proteolyses the membrane protein TRA-2A 
to produce a peptide that inhibits the masculinising protein FEM-3. Absence of TRA-
3 causes the transformation of hermaphrodites into pseudomales. In this case, TRA-
3 is seen as an important potentiator of its physiological substrate TRA-2A, which 
has feminising activity (78). 
 
 The C. elegans atypical calpains are expressed in a variety of tissues including 
neurons, intestine and body wall muscle (5). A systematic study of the calpains of C. 
elegans was performed by Joyce et al. (5). RNAi knockdown and deletion mutants of 
calpain genes yielded no observable phenotypes, suggesting either that there is 
functional redundancy between the C. elegans atypical calpains or that the 
functionality is difficult to discover through standard phenotypic measurements. clp-1 
and clp-4 are the only genes expressed in body wall muscle and RNAi knockdown of 
clp-1 or clp-4 did not cause myofibrillar disorganisation based on phalloidin staining 
of actin fibres (5). 
 
The atypical C. elegans calpain CLP-1 was overexpressed using the constitutively 
active muscle specific promoter of unc-54 in the body wall muscle of transgenic 
animals to simulate the over activity of calpain (5). Animals overexpressing CLP-1 





was attributed to the proteolytic activity of CLP-1 because this phenotype was not 
observed in animals overexpressing a catalytically inactive version of CLP-1 with an 
alanine residue substituted for the catalytic cysteine residue. EGL-19 is a C. elegans 
calcium ion channel subunit protein expressed in body wall muscle cells important 
for normal muscle contractions (80). egl-19(gf) mutants have inappropriately 
elevated Ca2+ levels (80). When CLP-1 was overexpressed in egl-19(gf) mutants, 
20% of adults displayed paralysis. Importantly, paralysis was suppressed when 
worms were treated with a Ca2+ ion channel inhibitor nemadipine-A, which 
specifically suppresses the activity of EGL-19 (5).  
 
In a C. elegans model of neurodegeneration, RNAi reduction of the calpain 
proteases clp-1 and tra-3 or the aspartyl proteases asp-3 and asp-4 resulted in a 
reduction in the number of cells undergoing necrotic cell death. RNAi knockdown of 
both aspartyl and calpain proteases did not further reduce necrotic cell death, 
indicating that the aspartyl and calpain proteases acted in the same necrotic cell 







1.9 This project 
 
Knowledge of calpains is based primarily on studies of typical calpains. The primary 
method of understanding the physiological role of a calpain is to identify substrates 
that are cleaved in vivo. This project focused on identifying atypical calpains 
substrates in body wall muscle using the model organism C. elegans. CLP-1 is 
required for necrotic cell death and overexpression has been shown to cause 
paralysis in adult C. elegans in a model of Duchenne muscular dystrophy (5,51). 
 
My project had 3 aims: 
1. To identify potential CLP-1 substrates in body wall muscle when CLP-1 is 
overexpressed in a C. elegans model of Duchenne muscular dystrophy. 
2.  To understand how CLP-1 is localised to sarcomere substructures in the body-
wall muscle of C. elegans. 







2 Materials and Methods  
2.1 Materials  
Unless otherwise stated materials were obtained from Sigma-Aldrich Corporation. 
  
2.1.1 Bacterial strains 
  
Escherichia coli (E. coli) XL-1 blue cells: recA1 endA1 gyrA46 thi-1 hsdR17 supE44 
relA1 lac [F´ proAB lacIq Z∆M15 Tn10(Tetr)]  
E. coli OP50: Uracil auxotroph.  
E. coli NA22: prototroph.  
 
2.1.2 C. elegans strains 
 
Strain Genotype Reference 
Bristol 
N2 
Wild type (64) 
PK1009 dpy-5(e61) I;bli-2(e768) II;unc-32(e189) III (81) 
PK1003 unc-5(e53) IV; dpy-11(e224) V; lon-2(e678) X (81) 
PK2969 qyIs43 [pat-3::GFP + ina-1(genomic) + unc-119(+)]; 
crEX467. 
(82) 
PK3085 unc-54::clp-1::mRFP crEX468 This study. 
PK3113 unc-54::mRFP crIs17 II This study. 
PK3114 unc-54::clp-1(C371A)::mRFP crIs18 X This study. 
PK3118 clp-1p::clp-1::GFP + pCoel::mRFP crEX484  This study. 
PK3142 unc-119(ed3); qyIs43 [pat-3::GFP + ina-1(genomic) 
+ unc-119(+)]; unc-54::clp-1(C371A)::mRFP crIs17 II 
This study. 
PK3143 unc-54::clp-1(C371A)::mRFP This study. 
PK3144 unc-54::mRFP crEX491 This study. 
PK3146 unc-54::clp-1Δ3::mRFP crEx499 This study. 
PK3149 unc-119(ed3); qyIs43 [pat-3::GFP + ina-1(genomic) 
+ unc-119(+)]; unc-54::clp-1::mRFP crIs18 X 
This study. 
PK3150 unc-119(ed3); qyIs43 [pat-3::GFP + ina-1(genomic) 
+ unc-119(+)]; unc-54::mRFP crIs19 
This study. 
PK2431 clp-1(tm690) (5) 
PK3163 unc-54::clp-1::mRFP crIs19 This study. 
PK3228 crEx501 [unc-54::clp-1Δ1::mRFP] This study. 









Name Description Reference 
pPJ107 pPD30.38 vector with unc-54::clp-1::myc insert. (5) 
pPJ108 pPD30.38 vector with unc-54::clp-1(C371A)::myc insert. (5) 
pMC7 pBSKSII+ vector with unc-54::clp-1::mRFP insert. (84) 
pCFJ151 A Multiple Cloning site vector that is used for MosSCI 
insertion at ttTi5605 location. Contains homology arms 
consisting of genomic DNA flanking the insertion site. 
(85) 
pRF4 Encodes a mutant collagen rol-6(su-1006) that causes 
worms to have a dominant roller phenotype. Used as a 
marker for microinjection. 
(86) 
pLN1 pCFJ151 vector with unc-54::clp-1(C371A)::mRFP 
insert. 
This study. 
pLN3 pBSKSII+ vector with unc-54::clp-1Δ3::mRFP insert. Δ3 
refers to a disruption mutation of domain 3 of CLP-1. 
This study. 
pLN4 pBSKSII+ vector with unc-54::clp-1Δ1::mRFP insert. Δ1 
refers to a disruption mutation of domain 1 of CLP-1. 
This study. 
pLN5 pBSKSII+ vector with unc-54::mRFP insert. This study. 
pLN6 pBSKSII+ vector with unc-54::clp-1Δ12::mRFP insert. 
Δ12 refers to a disruption mutation of domains 1 and 2 
of CLP-1. 
This study. 
pLN7 pBAD_myc_his_C with clp-1 isoform a cDNA insert This study. 
pLN8 pBSKSII+ vector with unc-54::clp-1Δ23::mRFP insert. 
Δ23 refers to a disruption mutation of domains 2 and 3 
of CLP-1. 
This study. 
pLN9 pBSKSII+ vector with unc-54::clp-1Δ2::mRFP insert. Δ2 
refers to a disruption mutation of domain 2 of CLP-1. 
This study. 
pLN10 pBSKSII+ vector with unc-54::clp-1Δ13::mRFP insert. 
Δ13 refers to a disruption mutation of domains 1 and 3 
of CLP-1. 
This study. 
pLN11 clp-4 del mutant gRNA_1 This study. 
pLN12 clp-4 del mutant gRNA_2 This study. 
 
 
2.1.4 Buffers and solutions 
 
1X H100 buffer: 100 mM KCl, 1 mM MgCl2, 50 mM (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) HEPES, 1 mM ethylene glycol tetraacetic acid 
(EGTA), 10% (w/v) glycerol. Prior to mixing with worms before homogenisation step 
add 1X Protease inhibitors (Roche), 1 mM phenylmethylsulfonyl fluoride, 0.5 mM 






10x TBE: 0.9 M TRIS-base, 0.9 M boric acid, 0.02 M EDTA. 
 
1.33x Gibson master mix: 1.33x isothermal buffer, Taq DNA ligase (New England 
Biolabs) 1000 units, T5 exonuclease (New England Biolabs) 20 units, Phusion DNA 
polymerase (New England Biolabs) 12.5 units. For 375 μl of Gibson master mix: 50 
μl taq ligase (40U/μl), 100 μl 5x isothermal buffer, 2 μl T5 exonuclease (1U/μl), 6.25 
μl phusion polymerase (2U/μl), nuclease free water 216.75 μl. 
 
1.5X H100 buffer: 150 mM KCl, 1.5 mM MgCl2, 75 mM HEPES, 1.5 mM EGTA, 15% 
glycerol, 2X Protease inhibitors (Roche). 
 
2x SDS sample buffer: 0.125 M TRIS-HCL pH 6.8, 20% (w/v) glycerol, 4% SDS, 3 
mM bromophenol blue, 0.2 M β-mercaptoethanol added prior to use. 
 
2x Nematode freezing solution: 0.1 M NaCl, 0.05 M KH2PO4, 30% (w/v) glycerol, 5.6 
mM Sodium hydroxide (NaOH). Autoclaved then 0.3 mM MgSO4 added. 
 
5x isothermal buffer: 25% (w/v) polyethylene glycol-800, 0.5 M Tris-hydrogen 
chloride pH 7.5 1.5ml, 50 mM magnesium chloride (MgCl2), 50 mM dithiothreitol 
(DTT), 1 mM deoxyadenosine triphosphate (dATP), 1 mM deoxythymidine 
triphosphate (dTTP), 1 mM deoxycytidine triphosphate (dCTP), 1 mM 







50x TAE: 2 M tris(hydroxymethyl)aminomethane) (TRIS-base), 1.9 M glacial acetic 
acid, 0.05 M ethylenediaminetetraacetic acid (EDTA) pH 8. 
 
Blocking buffer: 5% (w/v) non-fat dried skimmed milk (Marvel), 0.1% Tween 20 
(Melford), in PBS. 
 
Phosphate Buffered Saline (PBS): 0.14 M NaCl, 2.5 mM Potassium chloride KCl, 8 
mM Sodium dihydrogen phosphate, 16 mM KH2PO4. 
 
PBS-T: PBS, 0.1% (v/v) Tween-20. 
 
Ponceau stain: 0.1% (w/v) Ponceau S (P3504), 0.83 M acetic acid. 
 
Single worm PCR Lysis buffer: 50 mM Potassium chloride (KCl), 10 mM Tris-HCl 
(pH 8.3), 2.5 mM Magnesium Chloride (MgCl2), 0.45 % Nonidet P-40, 0.45% Tween 
20, 0.01% Gelatin, 0.01% Proteinase k. 
 
Sodium dodecyl sulphate (SDS) running buffer: 0.025 M TRIS-base, 0.19 M glycine, 
0.1% (w/v) SDS. 
 
TRIS-base/EDTA (TE) buffer: 0.01 M TRIS-Hydrochloric acid (TRIS-HCl) pH 8, 0.1 
mM EDTA. 
 







Premixed Luria-Bertani medium (LB) was prepared as directed (Sigma, L3022). 
1.5% LB agar plates were prepared by adding agar (Melford Chemicals, M1002) to 
LB medium prior to autoclaving.  
CaCl2 competent cells solution: 1 M CaCl2, 1 M piperazine-N,N’-bis(2-ethanesulfonic 
acid) (PIPES), 15% v/v glycerol.  
 
2.1.7 Antibiotics 
When required, antibiotics were added directly to media in the following final 
concentrations: 
Ampicillin: 100 μg/ml. 
Tetracycline: 12 μg/ml. 
2.1.8 Antibodies 
Nanotrap: RFP-Trap_A (ChromoTek, cat. no: rta-20) 
 
2.1.8.1 Primary antibodies 
polyclonal rabbit anti-RFP antibody (MBL, cat. no: PM005). Dilution: 1:1000 
MH4 mouse anti-intermediate filament subunit antibody (DSHB). Dilution 1:200  
MH24 mouse anti-vinculin Dilution 1:200 
MH25 mouse anti-beta integrin Dilution 1:200 
Mouse monoclonal anti-tubulin antibody (Sigma, cat. no: T5168) 1:1000 
 
2.1.8.2 Secondary antibodies 
ECL goat anti-rabbit IgG, HRP-linked whole Ab. Dilution: 1:5000 (Thermo) 






2.2 Molecular Biology Methods 
2.2.1 Agarose gel electrophoresis (Diagnostic and Extraction) 
1% (w/v) Agarose (Invitrogen) solutions were made with either 0.5x TBE or 1x TAE 
buffer, heated in a microwave and stored at 65°C ready for pouring. 
 
TBE gels were used for diagnostic purposes. Samples were mixed with 6x ficoll dye 
and electrophoresed at 65 V for 25-35 min in 0.5x TBE buffer alongside a DNA 
molecular weight ladder (Promega G5711) (87). The gel was then stained in 0.5 
μg/ml ethidium bromide (Bio-Rad) for >20 min before being visualised in a Gene 
Genius gene-doc system using GeneSys software. 
 
TAE gels were used to purify DNA fragments; samples were mixed with 4 μl of ficoll-
lite before being electrophoresed at 55 V for 1 hour in 1x TAE buffer (87). The gel 
was then stained with 1x SYBR Green (Thermo Fisher Scientific) for >30 min. DNA 
bands were visualised using a dark reader (Clare chemical) and the gel containing 
the band was excised using a razor blade. DNA was then extracted from the gel slice 
using a column-based QIAquick Gel Extraction Kit (Qiagen, cat. no: 28706) 
according to manufacturer’s instructions. 
 
2.2.2 Alkaline Lysis miniprep 
Single colonies were inoculated in 2 ml LB broth containing 100 μg/μl ampicillin and 
placed in an Innova shaking incubator (New Brunswick) at 37°C for 16-18 hours. 1.5 
ml of each culture was harvested, supernatant discarded, and pellet resuspended in 





supplies) / 0.2 M sodium hydroxide (AnalaR) was added and mixed by shaking. 150 
μl of 3 M potassium acetate / 2 M hydrogen acetate pH 4.8 was then added and 
mixed again by shaking. The mixture was spun at 15,000 xg for 3 min and 
supernatant transferred to a fresh Eppendorf tube containing 250 μl of isopropanol 
before being spun for another 3 min at 15,000 xg. The pellet was then washed with 
100 μl of -20°C 70% ethanol before being resuspended in 50 μl of TE buffer. 
Adapted from (88).  
 
2.2.3 Bacterial transformation of plasmids 
E. coli XL-1 blue competent cells were thawed by hand and immediately placed on 
ice. 0.1 – 0.5 μg/μl DNA was added to a pre-chilled glass tube with 100 μl competent 
cells, this mix was kept on ice for 20 minutes before being heat shocked for 2 
minutes at 42°C, then cooled on ice for 2 minutes before adding 250 μl LB broth and 
incubating at 37°C for 45-60 minutes. Transformation mixture was spread on LB 
agar plates containing 100 μg/ml ampicillin and incubated at 37°C for 18-20 hours.  
For blue/white selection 60 μg/ml X-gal (Melford) dissolved in N,N-
dimethylformamide and 0.12 mM Isopropyl β-D-1-thiogalactopyranoside (Melford) 
dissolved in Milli-Q H20 was spread on the ampicillin plates prior to spreading of the 
transformed bacteria (89). 
 
2.2.4 DNA restriction digest 
DNA was digested using the appropriate restriction endonucleases (New England 
Biolabs) in solutions containing buffer and BSA for times and temperatures 






2.2.5 Ethanol precipitation 
DNA was concentrated by adding 50 - 150 μg/ml glycogen (Promega), 0.1 volume of 
3 M Sodium acetate (Analar), 2 volumes of 100% ethanol and cooled in a -20°C 
freezer for >2 hours. The mixture was then centrifuged at 15,000 x g for 3 min and 
the supernatant removed using a pipette. The pellet was washed in -20°C 70% 
ethanol before being resuspended in 10 μl of either 1X TE buffer, 0.5X TE buffer or 
Milli-Q H20 depending on subsequent use2. 
 
2.2.6 Gibson isothermal Assembly 
Primers fused to synthesise PCR products for Gibson isothermal assembly reactions 
were designed with the help of the online NEBuilder tool (90). 10-100 ng of purified 
PCR products containing homologous overlaps was added to make up 5 μl DNA 
mix, which was added to 15 μl of Gibson assembly 1.33x master mix to make a final 
volume of 20 μl. The reaction was assembled on ice, before being incubated at 50°C 
for 1 hour in a PTC-225 Thermocycler (MJ Research) (91).  
 
2.2.7 Preparation of CaCl2 competent cells 
E. coli XL-1 blue was streaked onto a LB-agar plate containing 10 μg/ml tetracycline 
and incubated at 37°C overnight. Single colonies were used to inoculate vials 
containing 3 x 5 ml LB broth, which were then incubated at 37°C overnight in a 
shaking incubator. 5 ml of overnight culture was used to inoculate 420 ml of LB broth 
containing 10 μg/ml tetracycline in a 2 L flask, shaken at 200 rpm in an Innova 
shaking incubator (New Brunswick) at 37°C until OD690 reached 0.375.  
The culture was then split into ice cold 50 ml Falcon tubes, cooled on ice for 10 min 





the pellet washed with 10 ml of ice cold CaCl2 competent cells solution, this 
spin/wash step was then repeated, and the cells left to chill on ice for 30 min.  
The cells were then pooled into four 50 ml Falcon tubes, spun at 1250 x g at 4°C for 
5 min, supernatant discarded and pellet resuspended in 4 ml of ice cold CaCl2 
competent cells solution. Competent cells were then snap frozen with liquid nitrogen 
and stored at -80°C. Method adapted from (92). 
 
2.2.8 Polymerase chain reaction (PCR) 
High fidelity PCR was carried out using Phusion (New England Biolabs) according to 
manufacturer’s protocol. PCR reactions of 50 μl volume were prepared containing: 
1x HF buffer (New England Biolabs), 0.5 μM forward primer, 0.5 μM reverse primer, 
50-100 ng template plasmid DNA, 200 μM deoxyribonucleotide triphosphates 
(dNTPs), 1 unit Phusion polymerase (cat. No: M0530, New England Biolabs) and 
MilliQ water up to 50 μl.  PCR was carried out using a PTC-225 thermocycler (MJ 
research) using the following conditions: 98°C for 30 seconds, 25-35 cycles of 98°C 
for 10 seconds, 50-65°C for 20 seconds, 72°C for 15-30 seconds per kilobase of 
template followed by a final extension period at 72°C for 10 minutes. 
 
2.2.9 PureYield DNA miniprep 
Single colonies were grown in 5 ml LB containing 100 μg/μl ampicillin in an Innova 
shaking incubator (New Brunswick) at 37°C for 16-18 hours. 4.5 ml of bacteria was 
harvested and DNA was extracted using the plasmid Miniprep System kit 






2.2.10 Site directed deletion mutagenesis 
Primers were designed and used in a standard PCR to amplify the plasmid region 
flanking the targeted deletion site, thus excluding the deletion region from the 
amplicon (adapted from (93)). 2 units of DpnI (New England Biolabs) was added 
directly to the PCR product and incubated at 37°C for 30-60 min. 4 μl of the DpnI 
digested PCR product was used in a 20 μl ligation reaction to circularise the PCR 
product, containing; 1x T4 kinase buffer (New England Biolabs), 10 units T4 
polynucleotide kinase (New England Biolabs), 1 unit T4 ligase (New England 
Biolabs) and MilliQ water up to 20 μl. The ligation mix was incubated at room 
temperature for 20 min and product used to transform competent cells. 
 
2.3 Protein methods 
 
2.3.1 Bradford Assay 
Using the Pierce™ Coomassie (Bradford) Protein Assay Kit (cat. Number: 23200, 
Thermo Scientific) a BSA (diluted in relevant buffer) standard concentration against 
absorbance at 595 nm curve was made. Serial dilutions (0.5x, 0.25x, 0.125x) of 
sample were plotted against this curve to determine sample concentration as per 
manufacturer’s instructions. 
 
2.3.2 SDS-PAGE gel 
10% Acrylamide sodium dodecyl sulphate polyacrylamide gels were prepared in a 
Mini-PROTEAN® II Electrophoresis Cell (Bio-Rad). The gel was covered in water 
saturated butanol and left to set. Once set, a 4.75% acrylamide stacking gel was 





to be added. Protein samples were prepared by mixing with 2X SDS loading buffer 
and heating at 95°C for 10 mins prior to loading onto gel. The samples were 
electrophoresed at 100 V in 1X SDS-PAGE running buffer until the bromophenol 
blue dye had ran out the bottom of the gel (93). 
 
2.3.3 Silver Staining 
Polyacrylamide gels were stained using Pierce™ Silver Stain Kit (cat. Number: 
24612, Thermo scientific) according to manufacturer’s instructions. 
 
2.3.4 Western blotting and antibody staining 
Protein samples run on SDS-PAGE gels were transferred to nitrocellulose 
membranes (Amersham Protran 0.45 NC, cat. No.: 10600002, GE Healthcare) using 
a Mini-Protean II Cell Gel System (Bio-Rad) containing 1 litre of Western transfer 
buffer following the method of Towbin (94). The transfer was run at constant 40 mA 
at 4°C for 16-18 hours. The membrane was Ponceau S stained to assess protein 
transfer, then rinsed with MilliQ water to remove stain. The nitrocellulose membrane 
was then washed in 20 ml of blocking buffer and rocked for 30 min. The blocking 
buffer was removed, and the membrane was washed in 5 ml of PBS-T for 3x 5 min. 
Primary antibody diluted in blocking buffer was incubated with the membrane in a 
falcon tube for 1 hour. Nitrocellulose membrane was washed in PBS-T for 3x 5 min 
and the membrane was then incubated for 1 hour with secondary antibody diluted in 
blocking buffer before being washed for 15 min in PBS-T and then a final 3x 5 min 
wash in PBS-T. Membranes were then processed using SuperSignal West Pico 





manufacturer’s instructions before detection by Odyssey Fc Dual mode imaging 
system (Li-COR) with exposure of 2-10 minutes.  
 
2.4 C. elegans Methods 
 
2.4.1 CRISPR/cas9-mediated mutagenesis 
 
gRNA cloning (pLN11 and pLN12) 
 
3 μl of each 100 mM Complementary gRNA oligonucleotide was added to 10 μl 5X 
annealing buffer mixed with 44 μl of ddH2O to make a total volume of 50 μl  
Annealing mix was then heated to 95°C and allowed to cool to room temperature 
(~45 min). 
 
1 μl of annealed primers was then added to a 5 μl total volume ligation mixture 
containing: 1 μl of 50 ng/μl Bsa1 cut pRB1017, 2.5 μl of 2X rapid ligase buffer 
(Promega), 0.5 μl T4 ligase (Promega). The ligation mixture was incubated for 2 
hours at room temperature and transformed into 100 μl of XL-1 Blue cells. 
 
Colonies from transformation were screened for recombinants using M13_F 
and the specific gRNA antisense primer by bacterial colony PCR. Recombinant 









Young adult PK3161 [clp-1(tm690)] worms were injected with the following CRISPR 
mixture: pDD162 50 ng/μl, pJA58 25 ng/μl, PK1559 500 nM, pLN_11 30 ng/μl, 
pLN_12 30 ng/μl, PK1822 500 nM. After microinjection worms were placed on single 




5-6 days post microinjection, plates containing injected worms and their progeny 
were scored for: survival of parent, progeny displaying roller phenotype (count), 
progeny displaying dumpy phenotype (count). Lines with high numbers of roller and 
dumpy worms were considered ‘jackpots’ and were chosen for further screening. 
Progeny from ’jackpot’ plates were singled (40 – 75) on OP50 seeded plates, grown 
for 1-2 days at 20°C and allowed to lay progeny and subsequently screened by PCR 
for presence of the deletion mutation using primers PK1816 and PK1817. 
 
 
2.4.2 DNA Microinjection of worms 
Transgenic animals expressing extrachromosomal arrays were generated using the 
microinjection method as described by Mello et. al (86) . microinjection mixes 
contained 10 μg/ml of experimental plasmid, a co-expression marker (either 80 μg/ml 
pRF4 or 40 μg/ml pCoel::mRFP) that acts as a marker for successful microinjection 
and N2 genomic DNA to a total concentration of 90-100 μg/μl. Once injected, worms 
were placed on separate E. coli OP50 seeded plates. F1 progeny expressing the 
marker phenotype (roller) were placed on separate E. coli OP50 seeded plates and 
F2 progeny expressing the marker phenotype from these plates were used to 






2.4.3 Freezing of worms for long term storage 
For long term storage, C. elegans strains were kept at -80°C or in liquid nitrogen 
(64). To freeze a strain, 1.5 ml of M9 buffer was used to wash off each of three 
starved plates containing L1 worms into a 15 ml falcon tube, which was then spun at 
1200 rpm for 2 min in a centrifuge. Worms were pelleted at the bottom of the falcon 
tube; the supernatant was removed before 1 ml of 2x nematode freezing solution 
and 1 ml of M9 buffer was added. Mix was gently swirled before it was aliquoted into 
cryotubes (Nunc) which were subsequently placed inside a room temperature Mr 
Frosty TM freezing container (Thermo Scientific), which was placed inside a -80°C 
freezer and left for >24 hours. Frozen worms were thawed for use by hand and then 
poured onto an E. coli OP50 seeded NGM plate and left to recover in a 15°C 
incubator. 
 
2.4.4 General maintenance of C. elegans 
All strains of C. elegans used were cultivated in the lab on bacterial lawns of E. coli 
OP50 on single peptone Nematode growth medium (NGM) plates (referred to as 
seeded plates) and maintained at 15-25°C, according to the methods of Brenner 
(64). Integrated transgenic and N2 strains were maintained by chunking sections of a 
starved plate onto new plates. Worms expressing extrachromosomal arrays typically 
have low genetic transmission, so these worms were maintained by picking young 
adults using platinum wire with the associated phenotype onto new plates. 
 






To synchronise animals, 20-30 adult worms were picked to an E. coli OP50 seeded 
NGM plate and allowed to lay eggs for 3 hours before being picked off, the worms 
from this ‘timed egg laying’ plate were considered synchronous. 
30 Synchronised young adult worms were picked to a pre-warmed plate and 
subjected to heat stress at 35°C for 2 hours. Immediately after the 2 hour period 
worms were returned to 20°C and screened for paralysis and death and any 
abnormalities. Worms were screened again 2 hours later and every 24 hours for 3 
days (from t=0) (95). Significance testing between strains was performed using 
Fisher's exact test. 
 
2.4.6 Integrating extra-chromosomal arrays using irradiation 
50 L4 transgenic worms expressing the extrachromosomal array of interest were 
irradiated with 48 Gy from a 137Cs source. Irradiated worms (P0) were allowed to 
recover for 24 hours before groups of 2-4 irradiated animals were placed on E. coli 
OP50 seeded plates. Once grown, 10-20 F1 young adult progeny from each of these 
plates were picked individually onto new seeded plates (approximately 200-250 F1 
were picked in total). F1 progeny (F2) were allowed to develop before being scored 
based on percentage of F2 with transgenic phenotype. F2 from the F1 plates with 
the 10 highest transmission rates were then picked on to fresh seeded plates and 
strains with 100% transmission frequency were identified as integrated. As following 
the method described by Macmorris (96). Integrated strains were outcrossed with N2 






2.4.7 Liquid Culture 
5-8 uncontaminated 5 cm diameter NGM plates containing just starved C. elegans 
strain of interest were collected by washing plates with 5 ml of M9 buffer, allowing 
plates to stand for one minute and then transferring the wash into 15 ml falcon tubes. 
The worms suspended in M9 were centrifuged at 1200 rpm for 2 min at 4°C and 
supernatant discarded. The pelleted worms were washed twice more in M9. The 
worms were used to inoculate a 500 ml S-Basal complete medium containing E. coli 
NA22 in a 2 L volumetric flask. The inoculated media was then incubated in a 
shaking incubator at 20°C at 180-200 rpm for 3-4 days, until the majority of worms 
were young adults. The worms were harvested by settling the liquid culture in a 1 L 
glass cylinder partially embedded in ice for 4 hours. The media was then aspirated 
until there was approximately 50 ml left in the cylinder, the remaining liquid was 
transferred to 15 ml falcon tubes and the cylinder washed with M9 to elute remaining 
worms and the wash transferred to a 15 ml falcon tube. The suspended worms were 
centrifuged at 1200 rpm for 2 min at 4°C, supernatant discarded, worm pellets 
resuspended in ice cold M9, pooled together and centrifuged again at 1200 rpm for 2 
min at 4°C to yield 0.5 – 5 ml of packed worms. Packed worms were distributed into 
500 μl aliquots, mixed with an equal volume of 1X lysis buffer containing 2X protease 
inhibitor cocktail (Roche, Cat number: 04693159001) and then snap frozen 
individually in liquid nitrogen to form 1 ml aliquots of worm pellets which were stored 
at -80°C (97). 
 
2.4.8 Mapping of transgenes to chromosomes 
To determine which chromosome an integrated transgene was located on in a strain, 





32(e189) III] and PK1009 [unc-5(e53) IV; dpy-11(e224) V; lon-2(e678) X] 
respectively. PK1003 is homozygous for scorable phenotypes dumpy, blistered and 
uncoordinated. PK1009 is homozygous for scorable phenotypes uncoordinated, 
dumpy and long. 3-4 progeny F1 heterozygous worms were picked onto single 
plates. F2 worms were then picked to new plates respectively based on segregated 
plate phenotype, and the number of worms displaying the transgenic phenotype and 
without the transgenic phenotype were counted. Exclusion of the transgenic 
phenotype from F2 worms that are homozygous for a plate phenotype suggests that 
the transgene is present on that particular chromosome. 
  
2.4.9 Microscopy 
2.4.9.1 Fluorescence microscopy  
Fluorescence from worms expressing GFP and RFP were assayed using a Leica MZ 
FLIII fluorescence stereomicroscope using appropriate filters. 
 
2.4.9.2 Confocal microscopy 
Worms of interest were sedated using 1 mM levamisole 20 minutes prior to being 
mounted on set 3% agarose on glass slides for viewing using a Leica SP5 confocal 
system (with resonant scanner and hybrid detectors) (98). Fluorescent, DIC and z-
stack images were captured using Leica Application Suite Advanced Fluorescence 






2.4.10 Setting up worm crosses 
9-12 L4 males of a transgenic non-Unc strain of interest were put on a E. coli OP50 
seeded plate with 2-3 L4 hermaphrodites of desired cross strain and progeny were 
assessed for cross phenotype (99). 
 
 
2.4.11 Single Worm PCR 
Single worms were picked in to a PCR tube containing 2.5 μl of freshly prepared 
single worm PCR lysis buffer. The PCR tube was then placed in the -80°C freezer for 
>2 hours. After freezing, a drop of mineral oil was added to the PCR tube before it 
was incubated at 60°C for 1 hour and then at 95°C for 20 minutes in a PTC-225 
thermocycler (MJ research). PCR GoTaq reagents; 5 μl 5x GoTaq buffer (Promega), 
1.5 μl 25 mM MgCl2, 0.5 μl forward primer 10 μM, 0.5 μl reverse primer 10 μM, 0.2 μl 
25 mM Deoxyribonucleotide triphosphates (dNTPs), 0.125 units of GoTaq 
polymerase (Promega), 14.7 μl MilliQ H20 were then added directly to this PCR tube 
and PCR carried out according to manufacturer’s instructions. 
 
2.4.12 Whole worm Immunoprecipitation  
1 ml of snap frozen worms in H100 lysis buffer pellets were ground to a powder 
using a liquid nitrogen cooled pestle and mortar. The powder was thawed out at 
room temperature and immediately placed on ice and mixed with an equal volume of 
ice cold 1.5X lysis buffer containing 1x Protease inhibitor cocktail (Roche, Cat 
number: 04693159001), 2 mM PMSF, 1 mM DTT and 0.1% (v/v) NP-40. This mix 





homogenised mix was then centrifuged at 13.2 Krpm at 4°C for 10 min, the 
supernatant transferred to a new microcentrifuge tube and centrifugation/supernatant 
extraction repeated twice more. 20 μl of RFP nanotrap bead slurry (ChromoTek) was 
equilibrated in 500 μl of ice cold H100 buffer, centrifuged at 2500x g for 2.5 min at 
4°C and washed twice more in H100 buffer. Before incubation with the beads the 
lysate concentration was determined by Bradford assay and diluted to 2 mg/ml. 1 ml 
of HSS was added to the equilibrated beads and incubated at 4°C for 2 hours with 
constant mixing. After incubation period, incubation mix was centrifuged at 2500x g 
for 2 min at 4°C, 50 μl of supernatant was transferred to new Eppendorf and kept as 
unbound fraction and rest of supernatant discarded. Beads were resuspended in 500 
μl of ice cold H100 buffer with 1x Protease inhibitors, centrifuged at 2500x g for 2.5 
min at 4°C, resuspension and centrifugation steps were repeated twice more (100). 
Supernatant was discarded, and beads were then sent to a proteomics facility for 
mass spectrometry analysis or boiled in 2X SDS sample buffer for 10 min and 
pelleted and used in gel based analysis. For gel based analysis, immunoprecipitation 












3.1 Identifying potential CLP-1 substrates in body wall muscle by co-
immunoprecipitation and mass spectrometry. 
 
Overview 
Overexpression of the atypical calpain CLP-1 in body wall muscle was previously 
shown to cause a paralysis phenotype in a percentage of adult worms carrying the 
CLP-1 transgene in a C. elegans model of Duchenne muscular dystrophy (5). To 
extend this observation I sought to identify the structural proteins in muscle that 
might be proteolyzed by CLP-1. I will describe how I attempted to find substrates of 
the atypical calpain CLP-1 by co-immunoprecipitation (co-IP) followed by liquid 
chromatography tandem-mass spectrometry (LC-MSMS) as summarised in Figure 
10. The identification of potential substrates was based on differential co-IP using 
strains expressing either catalytically inactive CLP-1(C371A)::mRFP or mRFP alone 








Figure 10. Work flow of proteomic investigation into CLP-1 substrates. 
Transgenic animals were grown in batches then subsequently lysed. 
Immunoprecipitations of mRFP tagged proteins from lysate was performed, and co-
immunoprecipitated proteins were then identified by LC-MSMS. Analysis filtered out 
CLP-1 specific binding partners by comparison to an mRFP control. 
 
 
Alongside the proteomics experiment, it was also investigated if mammalian typical 
calpain substrates beta-integrin (PAT-3) (101), vinculin (DEB-1) (102) and desmin 
(IFA-1,2,3) (103) might be potential substrates of CLP-1 by co-immunoprecipitation 









3.1.1 Construction of transgenic C. elegans strains expressing catalytically 
inactive CLP-1(C371A)::mRFP and mRFP alone 
 
A catalytically inactive mutant of CLP-1 named CLP-1(C371A), which has a mutation 
causing substitution of the cysteine residue of the catalytic triad to an alanine, was 
used in this screen. CLP-1(C371A) was used to prevent cleavage of potential target 
substrates prior to co-IP and LC-MSMS. Previous work by Joyce et al. (2012) 
established that CLP-1::mRFP produced a similar phenotype to CLP-1::MYC when 
overexpressed in C. elegans body wall muscle (5), indicating that a C-terminal 
mRFP tagged CLP-1 retains its proteolytic activity. Therefore, it was concluded that 
C-terminal mRFP CLP-1 fusion protein would retain its ability to bind CLP-1 
substrates, and these substrates would be co-immunoprecipitated with CLP-
1::mRFP. A mRFP affinity tag was selected to tag CLP-1. mRFP fusion proteins are 
suitable targets for immunoprecipitation using RFP nanotrap (ChromoTek) (100). An 
mRFP tag was also chosen as the intracellular localisation pattern of CLP-1::mRFP 
could be analysed by in situ fluorescence microscopy. 
 
The plasmid clone pLN1, which expresses CLP-1(C371A)::mRFP under the control 
of the muscle constitutive promoter of unc-54 (104) (Figure 11), was generated by 
Gibson assembly using four PCR fragments from plasmids PCFJ151, pMC7 and 
pPJ108 (Figure 12). PCFJ151 is a worm expression vector (85), pMC7 contains 
wildtype cDNA of clp-1 with a 3’ mRFP tag and pPJ108 contains cDNA encoding 
catalytically inactive CLP-1(C371A) (84). Two PCR fragments were used to clone the 
vector region from PCFJ151, pCFJ151 5’ and pCFJ151 3’ (Figure 12). The unc-





1(C371A), which was amplified using primer pair PK1244 and PK1247 and template 
plasmid pPJ108, and clp-1::mRFP::3’UTR, which was amplified using primer pair 
PK1243 and PK1248 and template plasmid pMC7 (Figure 12). Gibson assembly 
products were validated by digestion with XhoI. Digestion of correctly assembled 
pLN1 with XhoI results in the detection of two bands of 10235 bp and 2153 bp. A 
clone matching this digestion pattern was chosen (Figure 13) and sequenced to 








Figure 11. Schematic of the clone pLN1. 
pLN1 expresses catalytically inactive CLP-1(C371A)::mRFP under the muscle 








Figure 12. PCR products used to construct pLN1 by Gibson assembly. 
1% TBE gel of PCR products used for Gibson assembly of pLN1. pCFJ151 5’ is a 
3690 bp PCR product generated using primer pair PK1241 and PK1245 on template 
plasmid pCFJ151, pCFJ151 3’ is a 3738 bp PCR product amplified using primer pair 
PK1242 and PK1246 on pCFJ151 template, unc-54::clp-1(C371A) is a 2686 bp PCR 
amplified product using primer pair PK1244 and PK1247 on template plasmid 
pPJ108 and clp-1::mRFP::3’UTR refers to a 2344 bp PCR product using primer pair 















Figure 13. Validation of plasmid pLN1 by XhoI digestion. 
Lane 1: DNA ladder. Lane 2 & 4: alkaline lysis minipreps of colonies grown from 
Gibson assembly product. Lane 3: bands do not correspond with Xho1 digest of 
pLN1, probable contamination from template plasmids used in PCR reactions for 
Gibson assembly fragments. Lane 5: bands of 10235 bp and 2153 bp correspond to 
Xho1 digest of pLN1. 
 
A strain stably expressing (50% transmission) the CLP-1(C371A)::mRFP 
extrachromosomal array, PK3143, was established by co-microinjecting pLN1 and 
the marker plasmid pRF4 into 20 adult N2 C. elegans. The F1 generation progeny 
were screened for the roller phenotype and F2 worms were screened for both the 
roller phenotype and mRFP fluorescence, as discussed in section 3.2. One line was 
found to express the CLP-1(C371A)::mRFP extrachromosomal array. The 
extrachromosomal array was integrated into the genome by gamma irradiation. To 
perform the integration, 50 L4 stage worms expressing CLP-1(C371A)::mRFP were 
exposed to 48 GY of radiation from a caesium-137 source. 250 F1 worms were 
picked onto individual seeded plates from irradiated parents and left to lay progeny. 
Integration of the array was expected to produce a 75% transmission rate amongst 
the F2 progeny. The five plates containing the highest frequency of worms 





expressing CLP-1(C371A)::mRFP as selected by eye were chosen and ten F2 
worms from each plate were placed singly on fresh OP50 seeded plates. From these 
50 plates, one F3 line showed 100% transmission and the strain PK3113 was 
established. PK3113 expressed CLP-1(C371A)::mRFP in 100% of animals. 
 
The plasmid clone pLN5 expressing mRFP alone under the control of the constitutive 
muscle specific promoter of unc-54 was constructed from pMC7 using site-directed 
deletion mutagenesis PCR (see section 3.2.1). This clone was microinjected into N2 
worms and the strain PK3144 (<30% transmission). This line was integrated using 
the same methodology used to construct PK3113, yielding strain PK3114.  
Exposure to gamma irradiation may result in background mutations in the genome 
outside of the desired extrachromosomal integration, as well as potential disruption 
of genes in the locus of where the array was integrated. To mitigate for background 
mutations, transgenic strains produced by this method were subsequently 
outcrossed 5x (96). 
Genetic mapping was performed on strains PK3113 and PK3114 to determine which 
chromosome contained the integrated extrachromosomal array. Each strain was 
crossed with mapping strains PK1003 and PK1009 and the F2 recombinants were 
assessed (Table 2 and 3). It was shown that in the strain PK3113 the unc-54::clp-
1(C371A)::mRFP transgene had been integrated into chromosome II, and in PK3114 





















No. of F2 worms 48 33 26 44 19 17 
No. of fluorescent 
worms 
25 1 14 22 11 10 
 
Table 2. Mapping the unc-54::clp-1(C371A)::mRFP transgene in PK3113. 
Fluorescent expression is excluded from F2 worms homozygous for a mutation on 
chromosome II indicating that the extrachromosomal array carrying the clp-

















No. of F2 worms 44 38 42 30 32 30 
No. of fluorescent 
worms 
33 19 28 16 24 0 
 
Table 3. Mapping the unc-54::mRFP transgene in PK3114. 
Fluorescent expression is excluded from F2 worms homozygous for a mutation on 
chromosome X indicating that the extrachromosomal array expressing mRFP 
transgene has been integrated into chromosome X. 
 
 
3.1.2 Characterisation of integrated clp-1(C371A)::mRFP and mRFP strains 
 
To assess the suitability of inactive CLP-1(C371A)::mRFP for use in co-
immunoprecipitation, the intracellular localisation of CLP-1(C371A)::mRFP was 
examined (section 3.2) using confocal laser scanning microscopy (CLSM). It was 
observed that both active CLP-1 and catalytically inactive CLP-1(C371A) were 
expressed in body wall muscle sarcomeres, localising to m-lines and adjacent to 
dense bodies (see section 3.2., Figure 32). Therefore, it was anticipated that CLP-








3.1.3 Solubility of CLP-1(C371A)::mRFP in different lysis buffers and 
immunoprecipitation of CLP-1(C371A)::mRFP 
 
Lysis buffers with different compositions of salts and detergents were tested in their 
ability to solubilise CLP-1(C371A)::mRFP from whole worm extracts. Ideally the lysis 
buffer would solubilise the protein of interest so that it could be immunoprecipitated, 
without being so harsh that it disrupts binding interactions with the protein of interest. 
When lysates were separated into supernatant and pelleted fractions, CLP-
1(C371A)::mRFP was present in the soluble fraction when worms were lysed with 
either H100 buffer containing 1% Triton X-100 or 0.05% NP-40 and 50 mM KCl.  
 
Lower lysis buffer detergent concentrations are usually recommended to reduce non-
specific binding, while preserving protein stability (105). 0.05% NP-40 has been 
recommended for immunoprecipitation of cytoplasmic proteins from C. elegans 
(106). Therefore, H100 buffer containing 0.05% NP-40 and 50 mM KCl was selected 
as the solubilisation buffer for co-immunoprecipitation. 
 
 
Once it was established that CLP-1(C371A)::mRFP was solubilised in 0.05% NP-40 
H100 buffer, it was next determined if it could be immunoprecipitated by an RFP 
nanotrap (ChromoTek). Figure 14 shows the different fractions (input, unbound, 
bound, flow) resulting from the immunoprecipitation of CLP-1(C371A)::mRFP and 
mRFP alone using RFP nanotrap (ChromoTek). Both CLP-1(C371A)::mRFP (~110 
kDa) and mRFP (27 kDa) were present in the input as expected (Figure 14). The 
band intensities of CLP-1(C371A)::mRFP and mRFP was slightly diminished but still 
detectable in unbound fractions, which were sampled after the initial lysate had been 
incubated with the RFP-nanotrap for 2 hours. This indicated that there was an 





band intensities of the bound fractions were increased compared to the input and 
unbound fractions suggesting enrichment by the RFP nanotrap of these proteins 
(Figure 14).  The flow fraction, taken from the final wash of the RFP nanotrap after 
the 2 hour incubation, showed no presence of the mRFP containing proteins.  
 
Figure 14. Detection of CLP-1(C371A)::mRFP and mRFP after 
Immunoprecipitation by RFP-nanotrap. 
Western blot of the input, unbound and bound fractions from the immunoprecipitation 
of CLP-1(C371A)::mRFP (~110 kDa) and mRFP (27 kDa) by RFP-nanotrap from 
whole worm lysates solubilised in H100 buffer with 0.05% NP-40. The degradation 

















3.1.4 Detecting differences in the proteins co-immunoprecipitated with CLP-
1(C371A)::mRFP and mRFP alone 
 
To compare the proteins being co-immunoprecipitated by  CLP-1(C371A)::mRFP 
and mRFP alone, the input and bound fractions were electrophoresed on a 10% 
SDS-PAGE gel and silver-stained (Figure 15). Several bands appeared to be 
enriched in the bound fraction of CLP-1(C371A)::mRFP when compared to the 
bound fraction of mRFP alone (Figure 15). 
 
 
Figure 15. Silver stain of the immunoprecipitation of CLP-1(C371A)::mRFP and 
mRFP from whole worm lysates. 
Some protein bands are enriched in the bound fraction of CLP-1(C371A)::mRFP (B) 
compared to the input lane (A). There are also protein bands that are enriched in the 
bound fraction of CLP-1(C371A)::mRFP compared to the bound fraction of mRFP 
(B). Arrowheads: enriched protein bands. 
 
Co-immunoprecipitation was replicated three times using three independent worm 
preps grown at 20°C. Lysis of these worm preps and co-immunoprecipitation of CLP-
1(C371A)::mRFP and mRFP alone were performed and the bound fraction sent to 

















3.1.5 Proteomic analysis  
 
Samples containing proteins co-immunoprecipitating with CLP-1(C371A)::mRFP and 
mRFP alone were electrophoresed on polyacrylamide gels. Gel lanes were cut into 
slices and digested with trypsin before performing high performance liquid 
chromatography and Orbitrap Velos (Thermo Scientific) tandem mass spectrometry 
analysis (107). Mass spectra collected from the orbitrap were subjected to a 
SEQUEST search against the theoretical mass spectra of all C. elegans proteins. A 
peptide spectrum match (PSM) occurs when the actual mass spectra is similar to the 
theoretical mass spectra of a C. elegans protein. To increase confidence in the 
identification of a PSM, the search was performed at False discovery rate (FDR) of 
1%. False discovery rate is assessed by the number of peptide spectrum matches 
observed in a control set of theoretical proteins, in this case the complete C. elegans 
proteome with the sequences reversed. 
 
3.1.5.1 Biological replicates show significant similarity 
 
Before performing statistical analysis on the proteomic replicate data, reproducibility 
between the replicates was analysed to ensure that subsequent analysis was 
meaningful. Pairwise comparisons between all replicates were performed; Spearman 
rank correlation and Pearson correlation was calculated for each pair of proteomic 
data (Table 4). Spearman correlation measures monotonicity of a relationship 
between two variables, and Pearson correlation measures linear correlation between 
two variables.  A minimum of 0.77 Spearman rank correlation and 0.94 Pearson 
correlation was observed between biological replicates, indicating correlation 





(108). As can be seen in scatter plots of the PSM count of proteins in each replicate 
pair (Figure 16) there are several proteins with large PSM counts (>1000), the 
presence of these proteins with large PSM count may affect Pearson’s correlation 
coefficient which is sensitive to outliers (109). Spearman’s rank correlation is not 
affected by the presence of these large PSM count outliers as it depends on the rank 
of the proteins not their PSM count, and so it is a more valid measure of correlation 
between these replicates. The pairwise comparisons showed that there was 
sufficient reproducibility between replicates to use them for statistical analysis when 
determining which proteins were enriched in the CLP-1::mRFP co-IP vs the control 



























































































Figure 16: Scatter plots of peptide spectrum match of replicate pairs. 
These plots show pairwise correlation between control replicates and between 
experimental replicates. Each replicate contains several proteins with large PSM 








































































Spearman 1 2 3 
1 X 0.85* 0.78* 
2 0.83* X 0.82* 
3 0.77* 0.79* X     
Pearson 1 2 3 
1 X 0.95* 0.97* 
2 0.95* X 0.97* 
3 0.98* 0.94* X     
Control 
   
Experimental 
   
 
 
Table 4. Pairwise Spearman and Pearson correlation of PSM data from the 
triplicate biological replicates of CLP-1::(C371A)::mRFP and mRFP alone. 
For both control and experimental co-IPs, the minimum Spearman rank correlation 
observed between biological replicates was 0.77. These values were >0.7 which is 
acceptable for this type of experiment (108). *all p-values < 0.01 for Pearson and 
Spearman correlation for each pairwise comparison. n for each pairwise comparison: 
control replicate pair 1 & 2; n = 1277, control replicate pair 2 & 3; n = 1267, control 
replicate pair 1 & 3; n = 1540, experimental replicate pair 1 & 2; n = 1607, 




3.1.5.2 Proteins enriched with CLP-1 
 
To identify proteins that form complexes with CLP-1(C371A)::mRFP a statistical 
analysis comparing the PSM counts of proteins identified in the mRFP co-IP vs the 
CLP-1(C371A)::mRFP co-IP was performed. Biological significance was measured 
by the fold change of the PSM count, and statistical significance was measured by 2-
sample Students t-test of PSM counts of the CLP-1(C371A)::mRFP co-IP and mRFP 
co-IP triplicates. Cut off values were used to narrow the number of positive 
interactors and reduce identification of false positives (110).  
 
SAINTexpress (significance analysis of interactome) is software used for 





mode Markov random field model (111). SAINTexpress was used to calculate the 
fold change (FC-a); when the PSM count was zero, it was replaced by 0.1 to avoid 
division by zero and enable statistical analysis (111). To assess the statistical 
significance of PSM counts identified in the experimental group of replicates versus 
the control group, a Students t-test with no assumption of equal variance was 
performed.  
 
Cut-off values of 2.5x fold change and p-value <0.05 were chosen to reduce 
likelihood of false positives. 57 proteins in total were identified that met these criteria 
(Table 5). This set of proteins was used to perform enrichment analysis and were 
further examined as potential CLP-1 substrates. As might be predicted, CLP-1 
showed the greatest fold-change of an average ~63x between the experimental and 
control co-IPs (Table 5). 
 
A volcano plot, plotted using Microsoft Excel, showing the distribution of significant 
hits from this experiment amongst all proteins identified in both runs was plotted 
(Figure 17). The grouping of proteins around CLP-1 and absence of this grouping in 
the control side (negative x-axis) indicates the presence of CLP-1 enriched partners 
and not mRFP specific enriched partners. 
 
3.1.5.3 Gene enrichment analysis and bioinformatics tool WormGRAB  
 
To assist with this analysis, I developed a bioinformatics tool named WormGRAB . 
When WormGRAB is provided a list of C. elegans prey proteins and a single bait 
protein input, it requests and processes information from the representational state 





information generated includes; available reagents including worm strains, 
antibodies and plasmids, as well as GO terms, expression and phenotypic data (79). 
WormGRAB (Figure 18, 19) also uses PubMed’s API to search for instances of co-
referencing between the bait and each prey protein, and then also searches for co-
referencing between their homologues. If a co-reference is identified, the unique 
PubMed IDs (PMIDs) for the relevant papers are retrieved (112). WormGRAB is 
implemented using a node.js http server that makes asynchronous calls to the APIs 
Wormbase and PubMed, implemented using a callback pattern (Figure 20). 
WormGRAB is free to access on all modern browsers at 
http://wormgrab.herokuapp.com/. The code repository for WormGRAB is available 
online at https://github.com/lauri3new/wormgrab. For phenotype enrichment analysis 






Figure 17. Volcano plot of proteins enriched in CLP-1::mRFP IP vs mRFP alone 
IP. 
Proteins (green) clustered with CLP-1 (red) are those that are enriched in the CLP-
































Accession Description* Fold 
change 
P34308 clp-1 encodes a calpain homolog. 63.04 
Q19132 F07A11.4 is an ortholog of human USP19 (ubiquitin specific peptidase 19). 8.01 
Q9N5G1 dhs-15 encodes a member of the short chain dehydrogenase/reductase family. 6.89 
O01884 coq-6 encodes a putative flavin-dependent aromatic-ring monooxygenase. 6.36 
P90904 K02B12.7 is an ortholog of human ArfGAP1 (ADP ribosylation factor GTPase activating protein 1) 5.55 
Q3HKC4 pcyt-1 encodes a lipid-activated CTP:phosphocholine cytidylyltransferase (CCT). 5.3 
Q23179 Microarray and RNA sequencing studies indicate that W05H9.1 is affected by Tryptophan… 5.86 
Q965R9 Y97E10AR.6 is an ortholog of human BSDC1 (BSD domain containing 1). 5.21 
O76566 unc-96 encodes a novel protein with no recognizable domains. 4.43 
H2L0N0 Microarray, proteomic, and RNA sequencing studies indicate that unc-132 is affected by cyc-1… 4.63 
P91270 F25B4.7 is an ortholog of human SLC25A4 (solute carrier family 25 member 4). 4.63 
Q9TZH8 T10B11.6 is an ortholog of human TMEM53 (transmembrane protein 53). 4.44 
O17766 lipl-7 is an ortholog of members of the human Lipases family including LIPF. 4.05 
Q9XUR4 T05F1.2 encodes a novel protein. 4.27 
Q7JPQ6 RNA sequencing and microarray studies indicate that B0361.3 is affected by jmjd-3.1… 3.86 
O61196 F37C4.6 is an ortholog of human PYROXD2 (pyridine nucleotide-disulphide oxidoreductase domain 2). 3.48 
G5EDP6 fmo-1 encodes a flavin-containing monoxygenase homologous to human FMO1, FMO2, and FMO3. 3.82 
P34666 coq-5 encodes a putative 2-hexaprenyl-6-methoxy-1,4-benzoquinone methyltransferase. 3.56 
Q93934 R07H5.8 is an ortholog of human ADK (adenosine kinase). 3.67 
Q7K6X4 npp-16 is an ortholog of human Nup50 (nucleoporin 50). 3.53 
Q18486 coq-8 encodes a putative protein kinase orthologous to ABC1 (COQ8) from S. cerevisiae and UbiB from E. coli. 3.63 
Q9U3Q6 ugt-22 is an ortholog of human UGT3A2 (UDP glycosyltransferase family 3 member A2) and UGT3A1. 3.53 
H2KYN0 vps-45 is an ortholog of human Vps45 (vacuolar protein sorting 45). 3.2 
Q9NET7 Microarray and RNA sequencing studies indicate that Y39B6A.10 is affected by Hydrogen sulfide. 3.35 
Q95QH4 F32A5.8 is an ortholog of human Wwox (WW domain containing oxidoreductase). 3.16 
Q9GYR8 Microarray and RNA sequencing studies indicate that C23G10.5 is affected by lin-15B, pgl-1, pgl-3, glh-4. 3.36 
G5ED43 fmo-5 encodes a flavin-containing monoxygenase homologous to human FMO1, FMO2, and FMO3. 3 
G5EBU3 zmp-3 is an ortholog of human Mmp1 (matrix metallopeptidase 1) and members of the MMP (M10 matrix 
metallopeptidases). 
3.19 
Q9U1Q2 gpi-1 encodes two isoforms of a putative glucose 6-phosphate isomerase orthologous to human GPI. 3.16 
I2HA81 Microarray studies indicate that F15B9.10 is affected by Humic substances… 3.02 
Q9XVI1 RNA sequencing and microarray studies indicate that T23G11.1 is affected by Ethanol… 3.02 
Q9N4G7 Y71F9B.2 is an ortholog of human TAMM41 (TAM41 mitochondrial translocator assembly and maintenance). 2.98 
Q09EE6 RNA sequencing and microarray studies indicate that K07A1.17 is affected by Rotenone… 2.96 
G5EF84 RNA sequencing and microarray studies indicate that gip-2 is affected by tatn-1… 2.95 
H2L0K4 Microarray, RNA sequencing, and tiling array studies indicate that Y45G5AL.1 is affected by hlh-30… 2.85 
Q09289 rpn-13 is an ortholog of human ADRM1 (adhesion regulating molecule 1). 2.97 
H1ZUX7 - 2.92 
Q9UAT3 mct-2 is an ortholog of members of the human SLC (Solute carriers) family including SLC16A3. 2.76 
Q9N3C2 Microarray and RNA sequencing studies indicate that Y54F10AR.2 is affected by cyc-1… 2.78 
Q9U2X0 prmt-1 encodes a type I protein arginine methyltransferase. 2.64 
Q9U2Y2 cdkr-3 is an ortholog of human CDK5RAP3 (CDK5 regulatory subunit associated protein 3). 2.72 
P54813 ymel-1 encodes an ortholog of human YME1L1. 2.52 
O17397 F52H2.6 is orthologous to the human gene 3BETA-HYDROXYSTEROL DELTA 24 REDUCTASE. 2.52 
Q93595 F26A3.1 is an ortholog of human LDAH (lipid droplet associated hydrolase). 2.57 
H2KMK6 Y38E10A.22 is an ortholog of human HSPBP1 (HSPA (Hsp70) binding protein 1). 2.64 
W6RY92 T12B3.4 encodes one of three C. elegans proteins orthologous to members of the MOB (Mps One Binder). 2.64 
Q8MXQ7 Y92H12BL.1 is an ortholog of human CDKAL1 (CDK5 regulatory subunit associated protein 1 like 1). 2.52 
O16487 Microarray, RNA sequencing, tiling array, and proteomic studies indicate that B0238.11 is affected by cgh-1… 2.64 
A4UVL1 Microarray and RNA sequencing studies indicate that D1086.17 is affected by nhr-114… 2.64 
P30639 lnkn-1 encodes a conserved, single-pass type I transmembrane glycoprotein. 2.64 
O02345 ZK896.9 encodes a Golgi apparatus transporter for UDP-glucose,  UDP-galactose, UDP-N-acetylglucosamine 2.64 
P46502 rpt-3 encodes a triple A ATPase subunit of the 26S proteasome's 19S regulatory particle (RP) base subcomplex. 2.67 
Q2HQK3 Y62E10A.20 is an ortholog of human C2orf47. 2.52 
Q7Z2A5 mop-25.1 encodes a protein orthologous to fission yeast Mo25p. 2.62 
O16266 Microarray and RNA sequencing studies indicate that F40A3.6 is affected by Methylmercuric chloride… 2.5 
Q21557 dlc-2 encodes a putative dynein light chain 1. 2.63 
Q21443 lmn-1 encodes the sole C. elegans nuclear lamin. 2.54 
Q17439 B0035.15 is an ortholog of human NDUFAF4 (NADH:ubiquinone oxidoreductase complex assembly factor 4). 2.51 
Table 5. 58 proteins that are most enriched in the CLP-1(C371A)::mRFP co-
immunoprecipitation. 
As expected the bait protein CLP-1 is the most enriched protein in the experimental 
co-IP. Fold change represents the average PSM ratio in experimental to control co-
IP experiments across all replicates and was calculated using SAINTexpress 










     
Term Expected Observed Enrichment 
Fold Change 
P-value Q-value 
multiple nuclei oocyte  0.23 3 13 9.30E-05 0.02 
muscle system 
morphology variant  
0.97 5 5.2 0.00046 0.051 
 
Table 6. Phenotype enrichment analysis. 
Phenotype enrichment analysis shows proteins important for proper muscle 
morphology that are enriched by co-immunoprecipitation with CLP-1.  
 
When CLP-1 is inappropriately activated, it could lead to dysregulated proteolysis of 
target substrates. In the case of substrates in body wall muscle, the resulting loss of 
muscle integrity could lead to paralysis. Under standard conditions CLP-1 might 
maintain proper muscle morphology by regulating the turnover of these proteins 
(10,77).  
 
It is possible that CLP-1 might also have a role in oocyte development given the 
enrichment of proteins with mutants producing multiple nuclei oocyte phenotypes, 
previously in starfish calpain was shown to be involved in meiosis reinitiation in 





3.1.5.5 Potential CLP-1 substrates 
 
To assess and narrow which proteins identified from the co-IP MS experiment would 
be selected for further validation, 3 subsets of the 57 proteins that met the cut off 
criteria were examined: the proteins with the greatest fold change (Table 7), the 
proteins that give rise to muscle disorganisation phenotypes when disrupted through 
RNAi or knockout (Table 8), and the proteins which have orthologues that have been 
previously identified as possible calpain substrates are displayed in Table 9. 
 
Accession Gene Description* Fold change 
Q19132 F07A11.4 F07A11.4 is an ortholog of human USP19 (ubiquitin 
specific peptidase 19). 
9.21 
Q9N5G1 dhs-15 dhs-15 encodes a member of the short chain 
dehydrogenase/reductase family. 
6.97 
O01884 coq-6 coq-6 encodes a putative flavin-dependent aromatic-ring 
monooxygenase, homologous to yeast COQ6. 
6.92 
P90904 K02B12.7 K02B12.7 is an ortholog of human ArfGAP1 (ADP 
ribosylation factor GTPase activating protein 1). 
6.35 
 
Table 7. Proteins detected by mass spectrometry (1% FDR) ranked by fold 
change. 
Fold change represents PSM ratio in experimental to control IP and was calculated 
using SAINTexpress. *Description abridged from Wormbase description (71). 
 
The proteins that were most enriched in the co-IP were FO7A11.4, DHS-15, COQ-6 
and K02B12 (Table 7). FO7A11.4 encodes an ortholog of human ubiquitin specific 
peptidase 19 (USP19). Interestingly, inactivation of USP19 was shown to decrease 
muscle atrophy in mice (115). COQ-6 monooxygenase is required for coenzyme q10 
synthesis. The electron chain component coenzyme q10 is primarily found in 
mitochondria and its deficiency has been associated with several diseases including 
Parkinson’s disease (116). It has also been investigated as a potential therapy for 








Accession Name Ortholog Description* Fold change 
Q3HKC4 pcyt-1 Phosphocholine 
Cytidylyltransferase 




Q9U2Y2 cdkr-3 CDK5 Regulation 
associated protein 
cdkr-3 is an ortholog of human 
CDK5RAP3 (CDK5 regulatory 
subunit associated protein 3); 
cdkr-3 is expressed in the 
pharynx, spermatheca, nervous 
system, and the intestine. 
2.83 
Q21443 lmn-1 nuclear Lamin lmn-1 encodes the sole C. 
elegans nuclear lamin. 
2.62 
 
Table 8. Targets identified in proteomic analysis that have orthologues that are 
possible calpain substrates. 
*Description abridged from Wormbase description (71). 
 
pcyt-1 encodes a lipid-activated CTP:phosphocholine cytidylyltransferase, which is a 
rate-limiting enzyme in biosynthesis of phosphatidylcholine. It was previously shown 
that oxidised low density lipids inhibited CTP:phosphocholine cytidylyltransferase via 
calpain degradation (118). Levels of phosphatidylcholine in human skeletal muscle 
are linked to insulin sensitivity and exercise response (119). 
 
CDKR-3 is an ortholog of human CDK5 regulatory subunit associated protein 3, 
although there is no evidence that calpain cleaves CDK5RAP3, calpain has been 
shown to digest the CDK5 regulatory protein p35 to produce the protein p25 and this 
cleavage is associated with neuronal apoptosis (120). 
 
lmn-1 encodes a nuclear lamin, nuclear lamins are possible calpain substrates in 
starfish (114). Nuclear lamins are fibrous proteins that are important for 
transcriptional regulation and structural stability of the nucleus. Degradation of 





in laminopathies with symptoms of muscular dystrophy, neuropathy and premature 
aging (122).  
 
 















T10B11.6 is an 




Yes - - Yes 4.51 





- Yes Yes Yes 6.13 
 
O76566 unc-96 unc-96 was identified 
in screens for 
mutations that disrupt 
body wall muscle cell 
structure. 
Yes Yes - Yes 5.10 
 
Table 9. Targets identified that produce muscle variant phenotypes in RNAi 
screens. 
Although not much is known about transmembrane protein 53’s function, it was 
found that a knockdown of NET4/TMEM53 in cell type caused premature 
senescence in primary fibroblasts (123). unc-96 mutants have decreased locomotion 
and myofibrillar organisation. UNC-96 is required for correct assembly and 
maintenance of C. elegans body wall muscle sarcomeres (124). *Description 
abridged from Wormbase description (71). **Phenotype information from RNAi 
screening (79). 
 
LMN-1 and TMEM-53 are nuclear and mitochondrial proteins, respectively. CLP-
1::mRFP was not detected in either of these structures (section 3.2) by LSCM. It 
might be the case that these are artefacts produced by the extraction process, or 
that they bound together in disrupted or apoptotic cells. Although the screen yielded 
a number of possible substrates, it remains necessary to validate these targets as 
calpain substrates. Some of the targets identified will likely be false positives 
(although steps were taken in the analysis such as using a 1% FDR) and not all 





validation experiments are further discussed in section 4.1.  However, due to time 
limitation these validation experiments were not able to be completed.  
 
 
Figure 18: WormGRAB protein and PPI data collection tool. 
WormGRAB gathers protein and gene data and literature references from 
Wormbase and Pubmed APIs about bait and prey proteins inputted by users via a 










Figure 19: WormGRAB interface and output. 
Using Uniprot accession identifiers as input, WormGRAB interacts with Uniprot, 
Wormbase and PubMed API’s to gather information that can be used to analyse co-







Figure 20. Node.js code snippet of WormGRAB. 
A code snippet of JavaScript code from WormGRAB, showing a http request to API 
call and http response processing. Multiple API calls are combined by the callback 
pattern to build up an array of arrays of data that is outputted as a tab separated text 







3.1.6 Candidate gene analysis 
 
 
Vinculin, beta-integrin (PAT-3) and intermediate filaments were investigated as 
potential binding partners of catalytically inactive CLP-1(C371A). Vinculin, beta-
integrin (PAT-3) and intermediate filaments are present in the sarcomeres of C. 
elegans body wall muscle cells and orthologues have been reported to be substrates 
for typical calpains (13,14,15). The crosslinking protein vinculin is found in the 
integrin attachment complexes of the sarcomere; M-lines, dense bodies and 
attachment plaques (see Figure 9). Beta-integrin plays a structurally important role in 
the sarcomeres of body wall muscle cells, anchoring dense bodies and m-lines to the 
sarcolemma. Intermediate filaments provide the link between the hypodermis and 
epidermis (42). 
 
To test for potential interaction between CLP-1 and these target proteins, co-IP by 
RFP nanotrap fractions of CLP-1(C371A)::mRFP and mRFP alone were analysed by 
SDS-PAGE and western blotting using mouse monoclonal antibodies MH4, MH24 
and MH25. MH4 recognises an intermediate filament subunit (125), MH24 
recognises vinculin (75) and MH25 recognises beta-integrin (126). It was expected 
that a binding partner would be detected against the CLP-1(C371A)::mRFP, but not 
mRFP alone bound fractions of the respective co-IPs. Candidates were lysed in 
H100 buffer containing low detergent 0.05% NP-40, high detergent (1% Triton X-
100) and high salt (300mM KCL) and the solubility and co-immunoprecipitation with 








Condition Soluble in 
0.05% NP-40, 
100 mM KCL 
Soluble in 
0.05% NP-40, 
300 mM KCL 
Soluble in 1% 




PAT-3 X X ✓ ✓ 
IFA-1 X X X X 
Vinculin ✓ ✓ ✓ X 
 
Table 10. Lysis buffers candidate proteins were tested in. 
PAT-3 was soluble when lysed in h100 buffer containing 1% Triton X-100, and co-
immunoprecipitated with CLP-1(C371A)::mRFP under these conditions. Vinculin was 
soluble in all lysis buffers tested but did not co-immunoprecipitate with CLP-
1(C371A)::mRFP. IFA-1 was insoluble in all buffers tested. 
 
3.1.6.1 Vinculin and Intermediate filaments  
 
Vinculin did not co-immunoprecipitate with CLP-1(C371A)::mRFP (Figure 21), 
indicating that vinculin is not a binding partner of CLP-1 and is unlikely to be a 
substrate, although it could be that vinculin is a transient or low-affinity binding 
partner and therefore not be detected in a co-IP experiment. Intermediate filament A 
(IFA) was not soluble in H100 buffer (Figure 22) or in high detergent or high salt 
conditions. A harsher lysis buffer could be used to solubilise IFA however it is 








Figure 21. Vinculin (~108Kda) does not co-immunoprecipitate with CLP-
1(C371A)::mRFP. 
Western blot of co-IP fractions stained for vinculin using MH24 primary antibody.  
Vinculin is the band at approximately 108 kDa. Vinculin is not present in the bound 
fraction of CLP-1(C371A)::mRFP. The band labelled N2 is a prep of 80 whole N2 




Figure 22. Intermediate filament A is insoluble in H100 lysis buffer. 
Western blot of co-IP fractions immunostained for IFA using MH4 primary antibody. 
IFA (~70Kda) is insoluble in H100 lysis buffer. IFA did not solubilise under increased 


























3.1.6.2 PAT-3 beta-integrin co-immunoprecipitates with CLP-1 
 
Beta-integrin was present in the insoluble fraction of the lysate only when frozen 
worm pellets were lysed in 0.05% NP-40 H100 buffer. When worm pellets were lysed 
in 1% Triton X-100 H100 lysis buffer, beta-integrin was present in the soluble input 
fraction. Beta-integrin was present in the bound fraction of the co-IP of CLP-
1(C371A):: mRFP but not of the co-IP of mRFP alone. This suggests that beta-
integrin forms a protein complex with CLP-1(C371A) (Figure 23). PAT-3 was not 
detected in the mass-spec analysis. Given that PAT-3 is not solubilised by the 
reduced detergent used in the lysis buffer for the proteomic experiment, it could 
explain why it was not detected. Further validation experiments are required to 
confirm if beta-integrin is a catalytic substrate of CLP-1. 
 
 
Figure 23. Beta-integrin co-immunoprecipitates with CLP-1(C371A)::mRFP. 
Immunoblot of IP fractions of CLP-1(C371A)::mRFP and mRFP stained with anti-
beta integrin antibody MH25. Beta-integrin (~110Kda) was enriched in the bound 


















3.2 Determining a minimal localisation domain of CLP-1. 
 
Overview 
The C. elegans sarcomere (Figure 9) consists of actin thin filaments anchored to the 
cell membrane via attachment to dense bodies, which are homologous in function to 
vertebrate z-lines. Actin thin filaments are interspersed with myosin thick filaments, 
which are anchored to the cell membrane by M-lines. M-lines form rows that are 
inter-digited with dense bodies (74,75). It was previously shown that a CLP-1::mRFP 
fusion protein driven from its native promoter localises to sarcomeric M-lines and cell 
contact sites in body wall muscle (5).  
 
To identify the region(s) of the CLP-1 protein that is responsible for promoting its 
localisation to m-lines and adhesion junctions, a series of plasmid clones expressing 
truncated CLP-1::mRFP fusion proteins under control of unc-54 muscle specific 
promoter were constructed. unc-54 encodes myosin heavy chain II, which is 
primarily expressed in body wall muscle cells (74). It was hypothesised that the 
series of truncated CLP-1 proteins would serve to delineate the region(s) responsible 
for localisation to sarcomere m-lines and adjacent to dense bodies. Truncated 
versions of CLP-1 were expressed as mRFP fusion proteins and the localisation 
pattern of each was examined by confocal microscopy. The design of truncations 
was guided by the domain architecture of CLP-1. All plasmids were constructed; 
however not all plasmids were microinjected. 
 
3.2.1 Construction of mRFP tagged CLP-1 truncation expression plasmids 
 
 
CLP-1 truncations were designed to delete singly or in combination the domains; 





1Δ2) and domain III (CLP-1Δ3) (Figure 24). Domain boundaries of CLP-1 were 
defined based on a multiple sequence alignment performed using Clustal Omega 
with other atypical C. elegans calpains, human typical calpains CAPN1, CAPN2, 
Drosophila CALPA (Figure 25) (127).To minimise structural disruption to the non-
truncated domains, 25 amino acids adjacent to the boundary were included from the 
disrupted domain in question. The majority of these adjacent amino acids belong to 
domain linker regions with no predicted secondary structure based on alignment with 
the crystal structure of CAPN2 (Figure 25). 
 
The plasmid clones pLN3, pLN4, pLN8, pLN9, pLN10 and pLN5 (Figure 24) were 
cloned using site directed PCR deletion mutagenesis starting with pMC7 as 
template. pMC7 encodes clp-1 cDNA with 3’ mRFP fusion under the control of 









Figure 24. CLP-1 truncation mRFP fusion proteins. 
Domain maps of wild type CLP-1 fused at the C-terminus to mRFP and the truncated 
fusion proteins CLP-1Δ1::mRFP, CLP-1Δ2::mRFP, CLP-1Δ3::mRFP, CLP-
1Δ12::mRFP , CLP-1Δ13::mRFP and CLP-1Δ23::mRFP designed to delete different 
regions of CLP-1.  
  








































Figure 25. Multiple sequence alignment of calpain proteins.  
Protein sequence alignment of C. elegans atypical calpains (CLP-1 to CLP-10) 
human calpains (CAPN1 and CAPN2) and D. melanogaster CALPA. Domain I 
(green) Domain II (red) Domain III (blue) are highlighted below the alignment. 
Conserved catalytic residues C, H and N are highlighted in cyan. CLP-3 lacks these 
catalytic residues. CAPN2’s sequence is highlighted with domains and linker regions 
attributed from its crystal structure (128); Domain I (purple), DI->DII linker (orange), 
Domain IIa (red), Domain IIb (pink), DII->DIII linker (orange), DIII (blue), EF hand 
domain (green). Proteins were aligned using Clustal Omega and shaded using 
Jalview 2.82. Dark blue boxes highlight greater than 80% sequence similarity, blue 
boxes >60% sequence similarity light blue boxes >40% sequence similarity and 









Plasmid clones pLN3, pLN4, pLN8, pLN10 and pLN5 were constructed similarly 
using one step site directed deletion mutagenesis with different primer pairs (Figures 
26, 27) to express different truncations of clp-1 cDNA fused to mRFP at the C-
terminus and also mRFP alone, under the control of the C. elegans unc-54 muscle 
specific promoter. pLN9, a plasmid that only expresses domain II was constructed by 
ligating two PCR products; the expression vector was amplified using primer pair 
PK1317/PK1323 from pMC7 and the domain II containing insert was amplified using 
primer pair PK1810/PK1811 from template plasmid pMC7 (Figure 28). 
 
The site directed deletion mutagenesis PCR products were then re-circularised and 
verified by using bacterial colony PCR or restriction digest. Minipreps of pLN3, pLN4 
and pLN5 were identified by Sma1 restriction digest (Figure 29). Bacterial colony 
PCR using primers PK1356 and PK1355 that span the entire clp-1 cDNA region 
were used to verify the successful truncation of domains from pLN6, pLN8, pLN9 
and pLN10 (Figures 30, 31). For all clones, the regions spanning the deletions were 
sequenced to confirm in frame truncation of the domain in question. The plasmids 
pLN3, pLN4, pLN5, pMC7 were microinjected into the germline of C. elegans 
PK2969 hermaphrodites (Method 2.4.2). The plasmids cloned and strains produced 








Table 11. Summary of the CLP-1 truncation clones that were generated and 
injected to produce transmitting lines. 
Strain PK3144 displayed fluorescence and was imaged by confocal microscopy, 
PK3228 exhibited no fluorescence.  
Plasmid Description Cloned Strains 
pLN3 Expresses CLP-1Δ3::mRFP that has a truncated domain 3 of 
CLP-1. 
Yes PK3144 
pLN4 Expresses CLP-1Δ1::mRFP that has a truncated N-terminal 
glycine rich region and domain 1 of CLP-1. 
Yes PK3228 
pLN6 Expresses CLP-1Δ2::mRFP that has a truncated domain 2 of 
CLP-1. 
Yes N/A 
pLN8 Expresses CLP-1Δ12::mRFP that has truncated N-terminal  
glycine rich region, domains 1 and 2 of CLP-1. 
Yes N/A 
pLN9 Expresses CLP-1Δ12::mRFP that has truncated N-terminal  
glycine rich region, domains 1 and 3 of CLP-1. 
Yes N/A 
pLN10 Expresses CLP-1Δ12::mRFP that has truncated domains 2 and 








Figure 26. PCR products: pLN3, pLN4 and pLN5 
PCR products amplified from pMC7; pLN3 is a 7419 bp PCR product with a 
disrupted CLP-1 domain 1. pLN4 is a 6906 bp PCR product disrupted domain 3. 
















Figure 27. pLN6, pLN8 and pLN10 linear PCR products generated by site 
directed deletion mutations of pMC7.  
pLN6 is a 6984 bp product using primer pair PK1667 and PK1666 in a PCR on 
pMC7 template causing a truncation of domain II. pLN8 is a 6021 bp product using 
primer pair PK1323 and PK1666 causing truncation of domains I and II. pLN10 is a 
6468 bp product using primer pair PK1667 and PK1317 causing truncation of 
domains II and III. 
  












Figure 28. pLN9 PCR products used for Gibson assembly cloning.  
1015bp Insert containing domain II was amplified from pMC7 using primers using 
PK1810 and PK1811. 5505bp expression vector containing unc-54 promoter was 
amplified using PK1317 and PK1323. 
  















Figure 29. Sma1 digests of pLN3, pLN4 and pLN5. 
A. Sma1 digest of plasmid DNA isolated from E. coli XL-1 blue colonies transformed 
with pLN3, ‘5’ has the correct band of 7419 bp. The bands from other colony 
minipreps correspond to the PCR template plasmid pMC7. B. Sma1 digest of 
plasmid DNA isolated from E. coli XL-1 blue colonies transformed with pLN4, ‘7’ has 
the predicted band pattern of a band of 5374 bp and another of 1532 bp 
corresponding to pLN4. C. Sma1 digest of plasmid DNA isolated from XL-1 blue 














Figure 30. Bacterial colony PCR confirming domain truncations of plasmids 
pLN6, plL8, pLN10 using primer pair PK1355 and PK1356. 
The amplicon produced by PCR using primer pair PK1355 and PK1356 spans the 
entire clp-1 cDNA. PCR using PK1355 and PK1356 on clones pLN6, pLN8 and 
pLN10 was used to confirm presence of truncation prior to confirmation by 
sequencing. Using PK1355 and PK1356 for PCR; truncation of domain II in pLN6 
results in a 1692 bp product, truncation of domain I and II results in a 666bp product 











Figure 31. Bacterial colony PCR of pLN9 clones using primers PK1356 and 
PK1355. 
The amplicon produced by PCR using primer pair PK1355 and PK1356 spans clp-1 
cDNA, truncation of domains I and III produces a 1125 bp product using primers 
PK1356 and PK1355 in a PCR.  
 
PK2969 expresses a PAT-3::GFP reporter, which is associated with dense bodies, 
m-lines and adhesion plaques, enabling easier identification of intracellular 
structures. From the microinjections stable lines transmitting extrachromosomal 
arrays were obtained; PK3144 [unc-54::mRFP crEX491], PK3146 [unc-54::clp-
1Δ3::mRFP crEx499], PK3228 [unc-54::clp-1Δ1::mRFP crEx501], Pk3083 [unc-
54::clp-1::mRFP crEX468]. The presence of target plasmids within 







3.2.2 Active CLP-1 and inactive CLP-1 localise to m-lines and adjacent to 
dense bodies in the sarcomere  
 
Confocal laser scanning microscopy (CLSM) was used to visualise the intracellular 
expression of fluorescent proteins in body wall muscle. The intracellular localisation 
of strain PK3114 [unc-54::clp-1(C371A)::mRFP crIs18 X] expressing catalytically 
inactive CLP-1 was also analysed. 
 
Although pLN4 was successfully injected to generate strain PK3228, PK3228 
exhibited no fluorescence. It is possible that this lack of fluorescence was due to a 
mutation in pLN4 in a region outside of the region spanning the deletion that was 
verified by sequencing. There was insufficient time to inject the other clones. Images 
of the muscle cells captured using a laser scanning confocal microscope (LSCM) 
showed that CLP-1::mRFP, CLP-1(C371A)::mRFP and CLP-1 were localised 
diffusely throughout the cytoplasm while being excluded from the nucleus (Figure 
32). pPJ83 was also injected and strain PK3118 [clp-1p::clp-1::GFP + pCoel::mRFP 
crEX484] expressing CLP-1::GFP under its native promoter was imaged (Figure 32) 
and similar diffuse cytoplasmic localisation was observed. GFP only expressed 
under a muscle specific promoter was also imaged (strain BC10095). 
 
As shown in Figure 33 panels A-F, mRFP by itself was diffusely expressed at the 
base of the sarcomere but like CLP-1::mRFP it was excluded from the dense bodies. 
CLP-1::mRFP, CLP-1(C371A)::mRFP and CLP-1Δ3::mRFP were enriched in m-lines 







Figure 32. Intracellular expression pattern of CLP-1 fluorescent reporters. 
A. mRFP and B. GFP expressed under control of muscle specific promoters are 
present throughout the cytoplasm and also accumulate in nuclei of body wall muscle 
cells. C . CLP-1::mRFP and D.CLP-1::GFP are present in the cytoplasm of body wall 
muscle cells but are excluded from the nucleus. Mitotic loss of extrachromosomal 
transgenes causes the mosaic pattern of expression observed in B and C (86). 













Figure 33. Intracellular localisation of CLP-1. 
CLP-1 localises to sarcomere m-lines and adhesion plaques in body wall muscle. (A) 
CLP-1::mRFP, (D) CLP-1(C371A)::mRFP, (G) CLP-1Δ3::mRFP (J) mRFP are 
expressed in body wall muscle. (B, E, H, K) PAT-3::GFP localises to myofilament-
sarcolemma attachment complexes; m-lines, dense bodies and adhesion plaques. 
(C) mRFP is excluded from the dense bodies. (F) CLP-1::mRFP, (I) CLP-





adhesion plaques and are enriched in between adjacent dense bodies, but not 
localised to dense bodies. Dense body, small arrow; arrowhead, M-lines; open 








3.3 Physiological analysis of calpains: Involvement of calpains in heat stress 




Heat induced stress in C. elegans was shown to induce an increase of calcium ion 
concentration in the muscle of C. elegans and adversely affect the locomotion and 
survival of adult worms (95). It was shown that adult C. elegans subjected to heat 
stress of 2-3 hours at 35°C had significant increase of intracellular Ca2+ levels and a 
decrease in locomotion and survival rates (129). Raising the temperature of the heat 
stress to 39°C led to widespread necrotic cell death (130). Resistance to heat stress 
including the suppression of increased calcium ion levels was observed in daf-2 
long-life mutants which have activated DAF-16 (129). 
 
Heat stress causes a similar phenotype to overexpression of CLP-1 in body wall 
muscle and increases calcium ion levels. Thus, it might be expected that high 
temperature would increase the activity of calpain due to the rise in Ca2+ levels. It 
was investigated whether calpain induced paralysis might be increased in heat 
stress conditions. To determine whether calpains are involved in the heat-stress 
pathogenesis the mutant CLP-1 overexpression transgenic PK3163 [unc-54::clp-
1::mRFP crIs19] strain, CLP-1 deletion mutant PK2341 [clp-1(tm690)] strain and 
wildtype animals were subjected to heat stress for 2 hours at 35°C. The animals 
were then examined for paralysis/death over the subsequent 3 days post heat stress 
and comparison of the percentage of paralysis/death exhibited by each strain was 
made. The percentage of paralysed/dead worms was also recorded for each strain 






3.3.1 Calpain is an aggravating factor in heat induced stress. 
 
 
Paralysed and dead worms were recorded at t=0 hours prior to heat stress, t=2 
hours after heat stress and every 24 hours (from t=0) for 3 days. At t=2 hours, after 
heat stress, it was observed that all worms were paralysed. In agreement with the 
observations of Momma et al. (95), it was observed that 26.7% (n = 60) WT adult 
worms exhibited paralysis/death after 3 days post heat stress at 35°C (Table 12). 
This percentage increased to 55% in heat stressed PK3163 worms overexpressing 
CLP-1::mRFP (Figure 34), indicating that CLP-1 overexpression increases heat 
stress induced paralysis/death (P-value <0.05). 
 
For non-heat stressed PK3163 worms overexpressing CLP-1::mRFP, 21.7% 
paralysed/dead worms were observed after 3 days (Table 13) and this increased to 
55% in heat stressed PK3163 worms (Figure 34). This result suggests that paralysis 
caused by calpain overexpression is increased (P-value <0.05, Fisher’s exact test) in 
heat stressed worms. Momma et al. (95) found that heat stress induced a spike in 
intracellular calcium ion levels. This might cause an increase in calpain catalytic 
activity. It is also possible that other pathological pathways are activated/upregulated 
during heat stress in combination with calpain over-activation. 
 
The number of paralysed/dead clp-1(tm690) worms did not significantly differ from 
wild type worms after 3 days under normal conditions (20°C) or 3 days after heat 
stress (Table 12, Table 13, Figure 34). 
 









genotype WT movement paralysed dead 
 
0 hours 
WT 60 0 0 
clp-1(tm690) 60 0 0 
[unc-54::clp-1::mRFP] 60 0 0  
2 hours 
WT 0 60 0 
clp-1(tm690) 0 60 0 
[unc-54::clp-1::mRFP] 0 60 0  
1 day 
WT 59 0 1 
clp-1(tm690) 54 1 5 
[unc-54::clp-1::mRFP] 49 4 7  
2 days 
WT 56 0 4 
clp-1(tm690) 54 0 6 
[unc-54::clp-1::mRFP] 36 10 14  
3 days 
WT 44 9 7 
clp-1(tm690) 45 3 12 
[unc-54::clp-1::mRFP] 27 17 16 
 
Table 12. Paralysis and survival of worms subjected to heat stress of 35°C for 
2 hours. 
An increased number of worms were paralysed/died after 3 days (P <0.05, Fisher's 
exact test) expressing the CLP-1::mRFP transgene compared to wild type worms 
after 2 hours of heat stress. The number of paralysed/dead clp-1(tm690) worms did 








genotype WT movement paralysed dead  
0 hours 
WT 60 0 0 
clp-1(tm690) 60 0 0 
[unc-54::clp-
1::mRFP] 
60 0 0 
 
2 hours 
WT 60 0 0 
clp-1(tm690) 60 0 0 
[unc-54::clp-
1::mRFP] 
60 0 0 
 
1 day 
WT 60 0 0 
clp-1(tm690) 60 0 0 
[unc-54::clp-
1::mRFP] 
51 5 4 
 
2 days 
WT 60 0 0 
clp-1(tm690) 60 0 0 
[unc-54::clp-
1::mRFP] 
48 3 6 
 
3 days 
WT 59 1 0 
clp-1(tm690) 59 1 0 
[unc-54::clp-
1::mRFP] 
47 5 8 
 
Table 13. Paralysis and survival of worms maintained at 20°C.  
A greater number of worms were paralysed/died after 3 days expressing the CLP-
1::mRFP transgene compared to wild type worms maintained at 20°C. The number 
of paralysed/dead clp-1(tm690) worms did not significantly differ from wild type 









Figure 34. Paralysis and survival rates of heat stressed wildtype (N2), clp-
1(tm690) and unc-54::clp-1::mRFP worms. 
White: Wild type mobility. Light grey: paralysis. Dark grey: dead. All worms were 
paralysed after the initial 2 hour heat stress treatment at 35°C. The percentage of 
paralysed/dead worms (n=60) was greater for adult PK3163 worms vs N2 worms. 
The percentage of paralysed/dead) PK2431 worms did not significantly differ from 
wild type worms after 3 days at 20°C. 
 
 
3.3.2 Attempted construction of a clp-1/clp-4 double knockout mutant by 
CRISPR-Cas9. 
 
Previously RNAi knockdown of muscle expressed calpains clp-1 or clp-4 showed no 
obvious phenotype in adult C. elegans. It was hypothesized this might be the 
consequence of functional redundancy (5). Construction of a clp-1;clp-4 double 













































To create a clp-1;clp-4 double mutant, CRISPR-Cas9 genetic engineering was 
attempted to create a 374 bp deletion of clp-4 was attempted in clp-1 deletion mutant 
strain PK2341 [clp-1(tm690)] (Figure 35).  PK2341 has a 624 bp deletion mutation in 
clp-1, and is predicted to express a protein lacking a complete catalytic triad and 
catalytic activity. Protospacer adjacent motif (PAM) sites were selected with aid of an 
online CRISPR-Cas9 design tool (131) and an online primer maker tool that I created 
named CrisprPrimerMaker (Figure 36). CrisprPrimerMaker automates a stage of 
sgRNA primer design for CRISPR-Cas9, following the method of Arribere et al. 
(132). PAM sites were targeted either side of the region to be deleted, and plasmids 
expressing single guide RNAs (sgRNA) targeting these sites were cloned (Figures 
37).  
 
28 worms were injected and 8 of these had progeny that contained dumpy or roller 
worms indicative of CRISPR-Cas9 activity. 50 worms were screened from one of the 
broods exhibiting the greatest number of dumpy and roller worms (42 dumpy and 3 
roller) by PCR, part of this screen is shown in Figure 38. None of the worms 
screened displayed a 309 bp band expected from deletion of the site targeted by the 
sgRNA.  
 
It is possible that no mutants were generated due to inefficiency of the targeted sites 
at being cleaved by Cas9, however it might also be due to the rarity of successful 


















lowercase : introns.  
UPPERCASE: EXONS. 
 
Yellow highlight: protospacer (length 19nt) 
Blue highlight: PAM site 
Purple highlight: Cas9 cut site 
Red highlight: cysteine of catalytic triad 
 
Figure 35. Protospacer adjacent motifs (PAM) sites targeted for clp-4 deletion 
mutation. 
Two PAM sequences were chosen to target the catalytic triad of clp-4 resulting in a 









Figure 36. Web interface and output of CrisprPrimerMaker. Automates a part of 
CRISPR-Cas9 primer design for use in pRB1017 plasmids. 
This tool automates a stage of sgRNA primer design for CRISPR-cas9 (following 
method of (132)) and prints back what mutation will be generated by the inputted 
primers and the predicted translation of the mutated gene 















Figure 37. cloning of pRB1017 single guide RNA expression plasmids. 
Bsa1 digested pRB1017 was ligated independently with annealed primers PK1813 
and PK1858 (sgRNA plasmid 1) and with primers PK 1815 and PK1859 (sgRNA 
plasmid 2) to produce two sgRNA expression clones. Clones were verified by 
bacterial colony PCR using M13_forward primer and the gRNA insert antisense 
primer to produce 600 bp products (plasmid 1 lanes 2-6 and plasmid 2 lanes 8-13). 
Lane 14: DNA ladder. 
  









Figure 38. PCR screen for clp-4 deletion mutation. 
Bands at ~700bp indicate wild type clp-4 gene, mutants would expect to have an 
extra band at ~300bp indicating deletion had occurred in one of the clp-4 genes. 
Bands 1 and 10 are DNA ladder. Bands 2-9, 11-17 are single worm PCR products 














4 Conclusion and Discussion 
 
4.1 Proteomic investigation into substrates of CLP-1 
 
An integrated transgenic mutant strain PK3113 of C. elegans expressing CLP-
1::(C371A)::mRFP and a control strain PK3114 expressing mRFP alone were 
generated. PK3113 and PK3114 integrated transgenes were mapped to the 
chromosomes II and X, respectively. Co-immunoprecipitation experiments using 
these strains were performed, and potential CLP-1 substrates were identified by 
differential comparisons. 
 
Statistical analysis using Students t-test, SAINTexpress to calculate PSM fold 
change, and cut-off values identified 57 proteins that have the potential to be CLP-1 
substrates. Potential substrates including orthologues of typical calpain substrates 
PCYT-1 and LMN-1, as well as novel interacting partners UNC-96 and TMEM-53 
were amongst the 57 proteins enriched in the CLP-1(C371A)::mRFP co-IP compared 
to the control co-IP of mRFP alone. Calpain mediated degradation of these proteins 
might be responsible for muscle degradation and paralysis observed when CLP-1 is 
overexpressed in muscle. It would be expected that above normal cleavage of UNC-
96 and PAT-3 by overactive CLP-1 in muscle cells would cause significant disruption 
to sarcomeres and release of myofibrillar proteins for degradation. If these proteins 







It is possible that false positives were identified amongst the 57 enriched proteins. 
For example, the proteasome regulatory protein RPN-13 is expressed in the nervous 
system, intestine and seam cells and not found in muscle cells (79). RPN-13 and 
other identified proteins from the proteomic screen might be artefacts caused during 
the lysis stage prior to IP, where CLP-1(C371A)::mRFP might have come in to 
contact with proteins from tissues other than muscle. However, CLP-1 is also 
expressed in other tissues including neurons under its endogenous promoter (5), so 
proteins expressed in tissues other than the muscle detected by the proteomic 
screen such as RPN-13 might still be identified from valid interactions and therefore 
potential substrates. False positives from the screen might also arise from other 
sources: the nature of the transgenic strain, the worm sample preparation as well as 
variation in the mass spectrometer used to capture MS spectra and identify proteins 
from the immunoprecipitations (133). There might have been false interactions 
caused by the increased transgenic expression of CLP-1::(C371A)::mRFP (96). It is 
also possible that the catalytically inactive CLP-1(C371A) has altered potential to 
bind substrates compared to wildtype CLP-1, therefore it is important that further 
validation studies are used to verify proteins identified from the proteomic screen as 
CLP-1 substrates. Given that CRISPR-Cas9 is now a viable option for generating 
transgenic worms, it would be of value to repeat the screen using CRISPR-Cas9 
integrated CLP-1::mRFP. Single copy expression would likely more closely 
reproduce the endogenous amounts of CLP-1 found in muscle cells, and might lead 
to fewer false positives being identified in the co-IP MS analysis. However, the co-IP 
MS might also be less effective at identifying true positives as there would be lower 







Previous work by Brule et al. (2) successfully identified typical calpain substrates 
from rat muscle tissue by immunoprecipitation of calpain using an anti-calpain 
antibody, followed by mass-spectrometry. The potential substrates identified from the 
calpain co-IP MS were then tested for co-localisation with CLP-1 in situ and in vitro 
cleavage by calpain.  
 
Other techniques for substrate screening include ORF display and yeast 2 hybrid 
screens. In ORF display methods, a cDNA library expressing proteins with C-
terminal biotin tags are bound to streptavidin and proteolysed by calpain causing 
release from the streptavidin. After sequential rounds of this process to eliminate 
non-specific targets substrates are identified by mass spectrometry (134). Yeast 2-
hybrid assays were used to discover protein-protein interactions between calpains 
and proteins expressed from cDNA libraries (135). However, both these techniques 
are likely to yield false positives due to exposure of the calpain to proteins that might 
not usually co-localise in vivo. By using transgenic CLP-1::mRFP it is possible to 
focus the proteomic study by expressing under a tissue specific promoter. In this 
study CLP-1::mRFP was expressed under a muscle specific unc-54 promoter. 
Another advantage of using transgenically expressed tagged CLP-1::mRFP is that 
the same worms can be used for imaging analysis. Immunoprecipitation of CLP-
1(C371A)::mRFP was performed using an RFP nanotrap (ChromoTek). The RFP 
nanotrap (ChromoTek) has advantages over traditional antibodies used for co-
immunoprecipitation experiments: it is derived from camelids and has a single light 
chain epitope recognising domain and it does not require protein A conjugation 





containing proteins. This is beneficial as fewer contaminating proteins are able to 
interfere with sample protein identification during mass spectrometry analysis.  
 
From the set of proteins that were determined to be enriched in the CLP-
1(C371A)::mRFP co-IP relative to the mRFP alone co-IP the most overrepresented 
GO terms included muscle system morphology variant. This is consistent with the 
hypothesis that CLP-1 is digesting muscle specific proteins that are important for 
structural and functional integrity leading to paralysis in the CLP-1 overexpression 
mutant. Under normal conditions CLP-1 might maintain proper muscle morphology 
by regulating the turnover of these proteins (10,77).   
 
In addition to proteomic analysis, 3 candidate proteins were tested as potential CLP-
1 substrates; intermediate filament, vinculin and pat-3. These proteins were tested 
for co-immunoprecipitation with CLP-1. PAT-3 co-immunoprecipitated with CLP-1 
under high detergent conditions; however, it did not appear as an enriched protein in 
the proteomic screen. It is likely that it was not solubilised in the lower detergent lysis 
buffer that was used to preserve protein-protein interaction for the co-IP followed by 
LC-MSMS. The cytoplasmic domains of beta-integrin were shown to be proteolysed 
by the typical calpain CAPN2/CAPNS in vitro (101). Calpains are proposed to have a 
physiological role in cell motility by cleaving focal adhesion proteins including integrin 
(31). pat-3(RNAi) was shown in adult worms results to disrupt sarcomeres and 
animal movement (77).  
 
The WormGRAB tool was produced that might be of use to other researchers when 





information about a protein dataset and assists in literature searches and could be 
used alongside other bioinformatics tools. It is available and free to access using all 
modern web browsers. 
 
4.1.1 Proteomic investigation into substrates of CLP-1: future work 
 
To continue this investigation substrate validation experiments could be performed 
by co-expressing GFP tagged proteins identified from the proteomic screen in: 1) 
active CLP-1 overexpressing mutants, 2) WT worms, 3) clp-1 null mutants and 4) 
worms treated with calpain inhibitors. GFP tags are commonly used in the worm 
community for tagging genes for localisation studies and mutant strains are often 
available. After co-expressing potential substrates and CLP-1, degradation of the co-
expressed target proteins could be determined by western blot analysis. It would be 
expected that CLP-1 substrates would be degraded in CLP-1 overexpressing 
mutants compared to a clp-1 knockout mutant, or possibly in the presence of a non-
specific calpain inhibitor. Cleavage products could be analysed by mass 
spectrometry to identify cleavage sites. 
 
It would also be of interest to perform the immunoprecipitation followed by mass 
spectrometry under different lysis conditions in case important CLP-1 substrates 
were not detected from the screen as they were not soluble in the H100 lysis buffer 
used. For example, using a lysis buffer with higher salt and or detergent 
concentration might result in a different population of proteins, such as was observed 






It would be beneficial for heterologous expression CLP-1 in E. coli to yield a 
functional protease, as this would allow faster and simpler testing of candidate 
substrates by co-expressing epitope tagged candidate proteins with CLP-1 in the 
absence or presence of calcium. Previously Joyce (2008) attempted to express his-
tagged CLP-1 using an IPTG inducible expression vector, however this yielded no 
soluble protein (136). Attempts to refold CLP-1 from inclusion bodies were also 
made, but yielded no functional CLP-1 proteins. I began another attempt at 
heterologous expression of CLP-1 in E. coli by cloning the plasmid pLN7 which 
expresses CLP-1 in an arabinose inducible expression vector (pBAD_myc_his_C), 
however I did not have time to perform any induction expression experiments. Other 
heterologous expression systems could be considered for co-expression of CLP-1 
and potential substrates identified from the proteomic screen, Sokol and Kuwabara 
(2000) expressed C. elegans CLP-5 (TRA-3) and it’s substrate TRA-2A in Sf9 cells 
using a baculovirus system (78). 
 
An RNAi screen followed by phenotypic scoring of either locomotion or sarcomere 
integrity by microscopy (of the targets identified by the proteomic screen) would help 
to identify proteins required for muscle development/maintenance. It is possible that 
a substrate of CLP-1 might produce a functional product upregulating muscle 
degeneration and paralysis. This kind of relationship is similar to the mammalian 
calpain substrate autophagy factor ATG-5, which when cleaved by calpain results in 
a functional degradation product that upregulates apoptotic cell death (46). To 
investigate if any of the proteins had this relationship, an RNAi screen of proteins 
identified in the proteomic screen and subsequent phenotype scoring could be 





phenotype observed in CLP-1 overexpressing worms would show that the protein in 
question likely produces a functional product that upregulates muscle degeneration.  
 
There are many online bioinformatics tools used to analyse proteomic data. 
WormMine is a datastore of C. elegans that can be queried against to retrieve 
specified information about a protein dataset (137). To construct queries for 
WormMine it is useful to have SQL knowledge, however it also has a query builder 
interface that can be used to generate queries. Textpresso is a text mining tool with 
features that include co-reference searching at sentence level and searching by 
biological concepts (138). WormGRAB was created as an opinionated tool to obtain 
experimentally useful data from multiple sources without requiring complex 
configuration, simply using a web browser. The WormGRAB web application could 
be expanded and enhanced by using natural language processing for the PubMed 
search to determine relationships between bait and prey. It could also be expanded 
to allow user configuration on what data sources are used and the amount of data 
retrieved. It could also be expanded to cover proteins in other species as well as co-
IP MS experiments that have multiple bait proteins. 
 
4.2. Determining a minimal localisation domain of CLP-1 
 
 
The plasmids pLN1, pLN3, pLN4, pLN5, pLN6, pLN8, pLN9 and pLN10  
encoding CLP-1::mRFP with different domain truncations (and mRFP alone) under 
control of a muscle specific unc-54 promoter were successfully cloned. Domain 





By microinjection lines stably expressing and transmitting the transgenes for 
plasmids pLN1, pLN5, pLN3 were established however there was insufficient time to 
inject the other plasmids.  
 
LSCM images were captured of the intracellular localisation of adult C. elegans body 
wall muscle sarcomeres for strains expressing CLP-1::mRFP, CLP-
1(C371A)::mRFP, CLP-1Δ3::mRFP and mRFP. In agreement with what was 
previously reported by Joyce et al. (5) on the localisation pattern of CLP-1::mRFP, 
CLP-1 is cytoplasmic diffuse but is also enriched at sarcomere m-lines and regions 
adjacent to dense bodies. I found that CLP-1(C371A)::mRFP localises similarly to 
CLP-1::mRFP and is also enriched at sarcomere m-lines and regions adjacent to 
dense bodies suggesting that catalytic activity is not required for normal localisation 
(Figure 16). CLP-1Δ3::mRFP localises similarly to CLP-1::mRFP suggesting that 
Domain III is not required for this localisation. 
 
A study characterising the intracellular expression patterns of 227 body wall muscle 
C-terminally tagged GFP proteins, not including CLP-1, discerned more than 15 
unique patterns of localisation in body wall muscle cells (139). CLP-1 is 
characterised as a cytoplasmic protein, however confocal microscopy allows greater 
resolution of z-field (depth) and CLP-1::mRFP was also found to be enriched at 
structures immediately adjacent to dense bodies and excluded from dense bodies at 








4.2.1 Determining a minimal localisation domain of CLP-1: future work 
 
 
This study could be continued by generating strains expressing all clp-1 truncation 
constructs. It might also be of interest to image worms under heat stress or in high 
Ca2+ background such as in an egl-19(gf) mutant, and see if the distribution of CLP-1 
changes within the sarcomere. Given that in vitro experiments observing expressed 
tagged truncated versions of CAPN1 found the C2-L Domain III was necessary for 
localisation to the plasma membrane under ionomycin induced activating conditions 
(140), it would be worthwhile to investigate if CLP-1 also undergoes translocation to 
the plasma membrane when intracellular Ca2+ levels are increased, and whether the 
C2-L domain III is also necessary for this process. 
 
To gain understanding of the functional importance of the domains of CLP-1, future 
work could determine which domains are required for CLP-1 proteolytic activity. The 
activity of truncated CLP-1 proteins could be measured if a substrate is successfully 
identified, and if degradation of this substrate can be observed by western blot. This 
would enable comparative analysis of a substrates degradation pattern between 
worms expressing full length and truncated CLP-1::mRFP and would indicate if the 
truncated domain is required for catalytic activity, depending on whether the 








4.3 Physiological analysis of calpains: Involvement of calpains in heat stress 
and attempted construction of a clp-1/clp-4 double knockout mutant. 
 
Momma et al. (95) found that intracellular Ca2+ levels are increased after heat stress. 
It is possible that calpains might be over activated during heat stress, and contribute 
to the paralysis and death exhibited by heat stressed worms (95). Enhanced 
paralysis/death was observed in worms exposed to heat stress that are 
overexpressing CLP-1 in body wall muscle compared to wild type animals. This 
might indicate that the level of active calpain in body wall muscle is a factor in the 
severity of phenotype caused by heat stress. clp-1(tm690) mutant worms also 
displayed similar levels of paralysis/death to wildtype worms after heat stress 
treatment, which suggests that either other C. elegans calpains are effecting the 
same phenotype after heat stress or that calpain is not the primary effector of this 
pathological phenotype. A greater number of worms should be assessed in future so 
that statistical analysis can be performed on the dataset, and video monitoring and 
locomotion software could be used to increase the accuracy of determining 
locomotion defects. 
 
To understand the role of calpains in body wall muscle an unsuccessful attempt was 
made to construct a clp-1;clp-4 double mutant because CLP-1 and CLP-4 are the 
only C. elegans proteins that have been found to be expressed in body wall muscle 
(5). sgRNA clones were designed and constructed that targeted deletion of a region 
of clp-4 that encodes catalytic triad. 28 worms were injected and 50 worms 
displaying the CRISPR-Cas9 co-conversion marker were screened but a mutant was 





occurred in injected worms due to dumpy and roller phenotype, however no mutant 
bands indicated no successful events. This might be due to rarity of successful 
events or the sgRNA not being optimised. In future it would be worth repeating the 
microinjections and also screening a greater number of worms. It might also be 
beneficial to repeat the microinjections with a different pair of sgRNAs still targeting a 
deletion of the catalytic triad of clp-4. 
  
4.3.1 Effects of Heat stress on clp-1 mutants and generating a clp-1;clp-4 
double mutant using CRISPR-cas9: future work 
 
A clp-1;clp-4 double mutant would be a useful reagent to test physiological functional 
of calpains in the C. elegans body wall muscle and could also be used for crosses 
with other calpain mutants or RNAi experiments, as RNAi efficiency is reduced when 
used for multiple genes (142). For further physiological analysis it would also be of 
interest to conduct Life span assays of clp-1(tm690), clp-1(tm690);clp-4(lf) mutants 
and worms treated with calpain inhibitor, and determine the relationship between 













Primer name Sequence 5' to 3' 
PK1241 pLN1 pCFJ_R GCCCACTAGTGAGTCGTATTATAAG 
PK1242 pLN1 pCFJ_F AGATCTTCGAATGCATCGC 
PK1243 pLN1 pMC7_insert_F gactcactagtgggcCCGGAAAACACAATAATGC 
PK1244 pLN1 pMC7_insert_R gatgcattcgaagatctTCTTCTTCTAAATTCCCATAAAATC 
PK1245 pCFJ151_F1 GCGGTAATACGGTTATCCAC 
PK1246 pCFJ151_R1 GTGGATAACCGTATTACCGC 
PK1247 pMC7_insert_F1 CGTTACTCGTTGGTAATCTGTC 
PK1248 pMC7_insert_R1 GACAGATTACCAACGAGTAACG 









PK1345 LN_mRFP_F ATGGCCTCCTCCGAGG 
PK1355 mRFP_5'_revseq CGCATGAACTCCTTGATG 
PK1356 unc-54_3'_fwdseq GCACTCATCACTCGCATC 
PK1631 pMC7_rev CATGCTAGCCAAGGGTCC 
PK1632 pMC7_fwd GCCTCCTCCGAGGACGTC 
PK1633 LN6_fwd cccttggctagcatgGCTGACGATGAGGAAGAA 
PK1634 LN6_rev gtcctcggaggaggcCAGTTCCCTGGAAAATATTG 
PK1635 pBAD_rev CCATGGTTAATTCCTCCTG 
PK1636 pBAD_fwd AACAAAAACTCATCTCAGAAG 
PK1637 LN7_fwd ggaggaattaaccatggGCTGACGATGAGGAAGAA 
PK1638 LN7_rev ctgagatgagtttttgttCAGTTCCTCCGACTCGAT 
PK1666 clp-1_DIIko_fwd cttggaccagatgttatgga 
PK1667 clp-1_DIIko_rev GAATTGTGGATCCTCGAATAG 
PK1668 pBAD_rev_1 GGTTAATTCCTCCTGTTAGC  
PK1669 pBAD_fwd_2 aacaggaggaattaaccATGGCTGACGATGAGGAAG  
PK1670 pBAD_clp-1_fwd tgagatgagtttttgttcCAGTTCCTCCGACTCGATAAATC  
PK1671 pBAD_clp-1_rev GAACAAAAACTCATCTCAGAAG 
PK1791 unc-54 3' UTR RV 
(anti) 
CATGTAGGGATGTTGAAGAG 
PK1792 clp-1_intron_tm690_F GGACTTTTGACCGACATTTATG 
PK1806 pLN11 egl-19_1 fwd CACACAAGCAGAAGATATTG 





PK1808 pLN11 egl-19_2 fwd CACCTTCCTCATTCAAGAC 
PK1809 pLN11 egl-19_2 rev GTCTTGAATGAGGAAGGTG 
PK1810 pLN9_insert_fwd gaggacccttggctagcatgCGACTATTCGAGGATCCAC  
PK1811 pLN9_insert_rev acgtcctcggaggaggccatTGCACCATCATGAGTATTTG  
PK1812 clp-4 del gRNA 1 fwd TTCTGCCGTAAAACTTTGATTTGG 
PK1813 clp-4 del gRNA 1 rev AAACCCAAATCAAAGTTTTACGGC 
PK1814 clp-4 del gRNA 2 fwd TTCTGCGGTAGTAAAGGGATGCGG 
PK1815 clp-4 del gRNA 2 rev AAACCCGCATCCCTTTACTACCGC 
PK1816 clp-4 del screening 
fwd 
gagaaatatgtcaaaataggcc 
PK1817 clp-4 del screening rev gctctcaacacgctgaattc 
PK1822 clp-4 del CRISPR-




PK1858 clp-4 del gRNA 1 
fwd_corrected 
TCTTGCCGTAAAACTTTGATTTGG 
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